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Bioorthogonal catalysis offers a strategy for chemical transformations complementary to 
bioprocesses and has proven to be a powerful tool in biochemistry and medical sciences. Transition 
metal catalysts (TMCs) have emerged as a powerful tool to execute selective chemical 
transformations, however, lack of biocompatibility and stability limits their use in biological 
applications. Incorporation of TMCs into nanoparticle monolayers provides a versatile strategy for 
the generation of bioorthogonal nanocatalysts known as “nanozymes”. We have fabricated a family 
of nanozymes using gold nanoparticles (AuNPs) as scaffolds featuring diverse chemical functional 
groups for controlled localization of nanozymes in biological environments, providing unique 
strategies for bioorthogonal imaging and therapeutic applications.   
My research is focused on modulating nanozyme surface chemistry for controlled 
localization of nanozymes at the site of interest for controlled bioorthogonal catalysis in 
mammalian and bacterial cells. In the intial studies, I have demonstrated controlled localization of 
nanozymes inside and outside the mammalian cell membrane. Nanozymes bearing cationic charge 
were used for activation of substrates inside the cells, owing to their high cellular internalization, 
whereas relatively impermeable zwitterionic nanozymes were used for extracellular activation of 
substrate molecules. Next, these cell-penetrating nanozymes were loaded inside the macrophages 
to develop a toolkit for targeting tumor site. With the inherent ability of macrophages to home in 
on tumor site, I demonstrated that nanozymes can generate chemotherapeutic drugs to selectively 
viii 
 
kill the cancer cells. This strategy has potential to reduce the off-target toxicity of the chemotherapy 
drugs. 
In subsequent studies, I utilized engineered bioorthogonal nanozymes to target bacterial 
biofilm infections. Functionalization of nanozyme surface with pH-responsive ligands enabled us 
to selectively image bacterial biofilms by targeting the acidic microenvironment of biofilms. In 
another strategy, nanozymes were non-covalently adsorbed on the surface of Red Blood Cells 
(RBCs) for selective killing of pathogenic bacteria. RBCs being highly susceptible to bacterial 
exotoxins were hemolyzed, resulting in selective accumulation of nanozymes at site of infection. 
These nanozymes in-turn activated pro-antibiotics at the site of bacterial infection to eradicate 
biofilms. Overall, these studies show strong potential of engineered nanozymes toolkit to generate 
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1.1 Bioorthogonal chemistry 
Bioorthogonal chemistry introduced the idea of carrying out selective chemical reactions 
with high efficiency in a complex biological environment with minimal interference to native 
biochemical processes.1-6 Chemical functional groups present in biological systems can act as 
reducing agents, nucleophiles, electrophiles and oxidants, however, bioorthogonal reactions are 
capable to proceed efficiently in presence of all these functional groups without interfering the 
native bioprocesses (Figure 1.1). The term “bioorthogonal chemistry” was first coined by Carolyn 
R. Bertozzi in 2003 to demonstrate Staudinger ligation reaction between an azide- containing 
unnatural sugar and a modified triphenylphosphine-fluorophore conjugate.7 Since then, synthetic 
chemists have explored new strategies to perform traditional organic reactions in accordance with 
biological systems. The reactions that were conventionally performed in a round bottom flask and 
test tubes in organic solvents, can now be performed in in vitro and in vivo biological environments.  
 
Figure 1.1. Scheme of a bioorthogonal chemical reaction, where the reaction between compounds 
A and B proceeds in presence of numerous functional groups present in a living system.  Adapted 
with permission from reference 3.   
Amongst multiple bioorthogonal chemical reactions, ligation reaction between two inert, 




“click chemistry” for azide-alkyne cycloaddition (CuAAC) exhibits fast kinetics and excellent 
bioorthogonality.8-12 However, high cytotoxicity of copper has resulted in scientists searching for 
alternative biocompatible ligation reactions. One approach utilizes biocompatible copper-free 
strain-driven azide-alkyne cycloaddition (SPAAC) between an azide and a strained alkyne (Figure 
1.2).12-15 In another approach, scientists have designed a series of ligands that can stabilize and 
decrease the toxicity of Cu(I).16 Alternatively, other transition metals such as palladium (Pd) and 
ruthenium (Ru) have been explored for catalyzing cross-coupling and olefin-metathesis reactions 
respectively.5  
 
Figure 1.2. a) The copper-catalyzed azide-alkyne cycloaddition (CuAAC). b) The Cu free click 
reaction of azides and alkyne (SPAAC). Adapted with permission from reference 12. 
Besides ligation reactions, bond-cleavage chemical reactions have been extensively used 
for providing bioorthogonal reactivity to the biological entities. In these chemical reactions, 
functional groups on substrates undergo bond cleavage to generate final product through 
bioorthogonal reactions (Figure 1.3). For example, o-nitrobenzyl (ONB) ether derivatives undergo 
UV-induced photo-decaging.17 Although, photo-cleavage reactions have demonstrated multiple 
applications, these strategies have a few major drawbacks such as photo-toxicity, low tissue 
penetration and need of specialized equipment.18 Additionally, the widely used ONB group may be 
decaged by nitroreductase present in hypoxic mammalian cells and bacterial cells, hence 




alternative strategies using small molecules and transition metal catalysts have been developed. 
The latter strategy (described in following section 1.2) is specifically more advantageous for 
carrying out bioorthogonal cleavage reactions in a precisely tunable, sustainable and minimally 
invasive manner.  
 
Figure 1.3. Representatives of bioorthogonal cleavage reactions. Typically, a masked drug, 
imaging agent or an enzyme is deprotected by UV light, small molecules or transition metal 
catalysts to their active state by bioorthogonal cleavage reactions. Adapted with permission from 
reference 4.   
1.2 Transition metal mediated bioorthogonal catalysis 
Transition metal catalysts (TMCs) have potential to overcome the drawbacks of photo-
uncaging and other similar bioorthogonal reactions. TMCs possess unique electro-chemical 
properties, enabling them to remove multiple protecting groups in a complex biological medium 
using a specific mechanism for each reaction. TMC-mediated reactivity provides the ability to 
chemically control the bond cleavage in a living environment without being dependent on location 
of the tissue and source intensity (Figure 1.4). These characteristics make TMCs an excellent 
candidate for bioorthogonal catalysis,21 - 24  however, stability of TMCs is reduced in complex 




        
Figure 1.4. Schematic diagram showing the comparison between a photo-uncaging and an 
organometallic catalyst mediated cleavage reaction. Organometallic catalysts can perform 
uncaging triggered by natural or light independent external stimulations, while, photo-uncaging 
relies on the light source and the operator. Adapted with permission from reference 21. 
 Researchers have developed multiple strategies for using TMCs in mammalian, bacterial 
cells and even more complex organisms such as zebra fish and mice. The pioneering study utilizing 
TMCs for uncaging reactions in living mammalian cells was performed by Streu and Meggers in 
2006. 25  They demonstrated that Ru based TMC [Cp*Ru(cod)Cl] (Ru1; Cp* = h5-
pentamethylcyclopentadienyl, cod = h4-1,5-cyclooctadiene) activated fluorescent molecules inside 
a living mammalian cells under biologically relevant conditions (Figure 1.5). They chose N,N-bis-
allyloxycarbonyl protected rhodamine 110 as the cellular probe. HeLa cells were incubated with 
substrates for 0.5 h, followed by washing with phosphate buffered saline (PBS). Upon addition of 
Ru-catalyst and thiophenol, rapid increase in fluorescence was observed due to cleavage of the 
allylcarbamate protecting group. Since then, numerous other Ru based catalysts were screened for 
faster kinetics and improved biocompatibility.26 , 27  In another work, Meggers and co-workers 
investigated aromatic azide as a masking group and pioneered uncaging azide protected amines in 
mammalian cells by using a combination of [Fe(TPP)Cl] (Fe1; TPP = 5,10,15,20-tetraphenyl-
21H,23H-porphin) and a thiol. 28  HeLa cells incubated with azide-rhodamine and Fe(TPP)Cl 
catalyst exhibited 28-fold fluorescence increase in the cytoplasm after 10 minutes. They further 




Although free TMCs successfully activated substrates in the short duration of these experiments, it 
became important to develop alternative strategies for minimizing the toxicity caused by these 
TMCs for long-term biological applications. Recently, there has been considerable progress in 
developing heterogeneous catalyst systems for bioorthogonal uncaging reactions in living 
environment.  
 
Figure 1.5. Fluorescence microscopy images of uncaging process of allylcarbamate-protected 
rhodamine 110 (pro-fluorophore) inside HeLa cells using ruthenium nanocatalyst. a) Right after 
catalyst addition and b) after 15 min. Adapted with permission from reference 25. 
Unciti Broceta and Bradley et al. developed a biocompatible cell-internalizable Pd0 based 
heterogeneous catalyst system to minimize the toxicity caused by free metal ions.29 They combined 
two techniques: an amino functionalized polystyrene microsphere as a delivery vehicle and 
entrapment of Pd nanoparticles (PdNP1) within cross-linked resin beads. These PdNPs were 
upaken by the cells, then these NPs  activated alloc-rhodamine substrate and performed Suzuki-
Miyaura cross-coupling reaction within the cytoplasm (Figure 1.6). This was the first example 
utilizing a bioorthogonal heterogeneous palladium catalyst to perform non-natural chemistry in the 
cytoplasm of human cells. Subsequently, Unciti Broceta and Bradley et al. developed palladium 
macroscpheres (PdNP2), for extracellular activation of propargyl protected 5-Fluorouracil (5-
FU).30 In further studies, they used palladium-mediated bioorthogonal chemistry to activate other 
cytotoxic drugs such as gemcitabine and floxuridine.31-34 These studies highlight the enormous 




Moreover, synthetic carriers play a critical role in enhancing the catalyst stability and controlling 
their selectivity for increased efficacy of the bioorthogonal strategies.     
 
Figure 1.6.  Pd0-mediated allylcarbamate cleavage within HeLa cells. a) Pd0-catalysed intracellular 
deprotection of reagent 1 generates fluorescent compound 2 b) Pd0-mediated Suzuki–Miyaura 
cross-coupling within HeLa cells: cross-coupling of reagents 3 and 4 generates the mitochondria-
localized fluorescent compound 5. Adapted with permission from reference 29.  
1.3 Fabrication of gold nanoparticles  
Delivery of therapeutic molecules to specific physiological targets is a key challenge. In 




applications including metal nanoparticles, dendrimers and polymeric micelles.35-43 Among all 
these nanocarriers, gold nanoparticles (AuNPs) are particularly promising owing to a number of 
desirable characteristics.44-49 Firstly, gold core is relatively non-toxic and inert. Secondly, AuNPs 
can be easily functionalized with surface structures for modulating interaction with biological 
entities. Finally, AuNPs can be easily tracked and quantified by mass spectrometry. A popular 
approach to synthesize the Au core is reducing gold salt (HAuCl4) by Commonly, thiol-protected 
AuNP core is synthesized following biphasic strategy pioneered by Brust-Schiffrin. 50  In this 
method, Au salt (HAuCl4) is transferred to organic phase by a surfactant tetraoctylammonium 
bromide (TOAB) followed by reduction of Au salt by sodium borohydride (NaBH4) in presence of 
alkanethiols. Next, AuNPs are coated with monolayer of appropriate ligands following Murray 
place exchange reaction taking advantage of strong gold-thiol affinity. 51  After ligand 
functionalization, AuNPs are characterized for size, surface charge and ligand density.  
The AuNPs described in this dissertation were developed by several generation in Rotello 
group.46,47 Briefly, it has a 2 nm gold core and ligands are attached to the core through a thiol anchor. 
The ligand monolayer consists of three crucial components (Figure 1.7): a) a long aliphatic chain 
composed of 11 carbons to provide particle stability52 b) a spacer of four ethylene glycol units to 
provide biocompatibility, the length of the spacer was optimized to minimize aggregation in 
biological fluids53,54 and c) a functional group to modulate the interaction with biological entities. 
Using this methodology NPs can be functionalized with distinct headgroups allowing us to 
ascertain the interactions of these functional groups with biosystems in a quantitative fashion. 
Specific design of surface structure can dictate enhanced uptake by specific cell type, payload 





Figure 1.7. Schematic representation of engineered nanoparticles used in this dissertation. 
1.4 Engineered gold nanoparticles for drug delivery 
Engineered AuNPs represent an excellent candidate for drug delivery due to high surface 
area and tunability. For example, therapeutic molecules attached to the monolayers can provide 
controlled and sustained drug release. Therapeutic molecules can be attached to AuNPs either by 
covalent coupling or non-covalent adsorption. Mirkin et al. demonstrated conjugation of paclitaxel 
(a potent chemotherapeutic drug) to AuNPs via DNA linkers, thereby enhancing the solubility and 
overall effectiveness of the drug.55 Similarly, Zubarev et al. attached the same drug to phenol-
terminated AuNPs through a flexible hexaethylene glycol linker.56  Mirkin, Lippard and coworkers 
developed a strategy to covalently conjugate  Pt(IV) prodrugs to oligonucleotide AuNPs, exhibiting 
enzyme mediated intracellular activation of the prodrug into active form of Pt(II), resulting in 
enhanced cytotoxicity relative to free drugs. 57 Moreover, Intracellular prodrug activation reduced 
the side effect of drug, attributing to delivery in an inert form.  
Alternatively, prodrugs can also be activated/released intracellulary by glutathione (GSH) 
mediated activation/cleavage, provides a non-enzymatic stimuli-based strategy. Rotello et al. 
demonstrated GSH mediated intracellular release of a hydrophobic dye (Bodipy) from monolayer 
functionalized AuNPs.58 They used a cationic AuNP for enhanced cellular uptake and the dye 
release was observed attributing to fluorescence quenching ability of AuNPs. Alternatively, the 
drugs can be attached non-covalently to the NPs, providing a strategy for direct release at the 




hydrophobic pocket present in the monolayer structure (Figure 1.8). The radial arrangement of the 
ligands creates a hydrophobic interior inside the monolayer of the AuNPs that can used to load 
hydrophobic drugs in the cavity. Whereas, outer surface chemistry can be used to regulate the 
interactions of the AuNPs with cell membranes. Rotello et al. used a zwitterionic functionalized 
AuNPs for minimizing non-specific binding with biomacromolecules and preventing cellular 
uptake.59 The hydrophobic dye/drug molecules were encapsulated in the hydrophobic pocket by 
using solvent displacement method. The payload was released by membrane-mediated diffusion to 
MCF-7 cells. The AuNPs were found to be excellently biocompatible causing minimal toxicity to 
the cells.   
 
Figure 1.8. Schematic representation of AuNP containing monolayer entrapped drugs and their 
delivery into cells through monolayer membrane interaction. Adapted with permission from 
reference 59. 
1.5 Engineered nanoparticles for bioorthogonal catalysis: Nanozymes 
Building on the previous work encapsulating hydrophobic dye/drug in the surface 
monolayer, Rotello and co-workers used the same strategy to encapsulate hydrophobic TMCs into 
the monolayer of water soluble ~ 2 nm core gold nanoparticles (AuNPs) providing the TMCs 
biocompatibility and stability (Figure 1.9).60-65 The long aliphatic chain in the AuNPs were used to 
encapsulate hydrophobic TMCs. This strategy provides a general platform that solubilizes 
hydrophobic catalyst preserving their activity and stability. These AuNP-catalyst complexes were 
termed as “nanozymes”, due to their nanometric particle dimensions and catalytic activity 




method used in the previous study.59 Briefly, water soluble AuNPs were mixed with organic 
solution of TMCs. The organic layer was slowly evaporated, and the excess catalyst was removed 
by multiple filtration cycles including molecular cut-off filter and dialysis. The catalytic activity of 
the nanozymes were assessed by activation imaging and therapeutic agents in solution and in in-
vitro models. 
 
Figure 1.9. Schematic representation of nanozymes used in this dissertation. Adapted with 
permission from reference 60. 
After establishing the nanozyme toolkit, Rotello and coworkers developed a strategy to 
regulate the catalysis of nanozymes using host-guest supramolecular interactions.61 The catalytic 
activity of nanozymes was reversibly controlled by using cucurbit[7]uril as a “gate-keeper”, 
attributing to supramolecular interactions between cucurbit[7]uril and ligand terminal group. This 
“gate-keeper” turns the nanozymes catalytically inactive until a guest molecule 1-adamantylamine 
(ADA) is added to displace the cucurbit[7]uril molecules. The efficacy of this supramolecular 
gated-activation system was demonstrated by the activation of allylcarbamate-caged pro-
rhodamine and propargyl-masked 5-FU in HeLa cells. The substrates could be activated only in 
absence of “gate-keeper” or after the addition of the competing guest ADA when cucurbituril was 





Figure 1.10. Schematic diagram of supramolecular regulation of intracellular catalysis a) substrate 
activation by bioorthogonal nanozyme in mammalian cell b) a gate-keeper molecule forms a 
complex with the ligand headgroup and inhibits catalytic activity c) catalysis is restored by addition 
of a guest molecule which replaced the gate-keeper. Adapted with permission from reference 61. 
1.6 Dissertation overview 
Site-specific localization of nanozymes is crucial for generating imaging and therapeutic 
molecules at the desired site for targeted imaging and drug delivery. The surface engineering of 
nanomaterials dictates their interaction with biological cellular systems and plays a pivotal role in 
determining the spatiotemporal localization of the nanozymes. In this thesis, I have focused on 
tuning the surface chemistry of nanozymes for controlling their localization and bioorthogonal 
catalysis inside-outside of cell membrane, targeting tumor site and bacterial biofilms.  
In the Chapter 2 of this thesis, I have demonstrated intra and extracellular localization of 
nanozymes in mammalian cells. I have utilized a cell membrane penetrating cationic nanozyme for 
intracellular localization and a stealth zwitterionic nanozyme for extracellular localization. The 
spatial localization was demonstrated by activating two pro-fluorophores of different wavelengths 
and polarity inside and outside the cell membrane. We next compared therapeutic efficacy of intra 
vs extracellular activation of pro-chemotherapeutic drug. By exploiting the ability to regulate 
nanozyme-cell interaction through appropriate surface functionalization, I designed a highly 
modular system for in-situ generation of diagnostic and therapeutic agents at both inside and 
outside the cell membrane. This strategy provides a novel toolkit to regulate important cellular 





Building on these studies, In Chapter 3, I further explored the ability of these engineered 
nanozymes to target tumor sites. Targeting the tumor microenvironment has emerged as a 
prominent strategy in cancer therapy to overcome the lack of specificity of conventional 
chemotherapy techniques. Macrophages have demonstrated ability to migrate across 
chemoattractant gradients and are actively recruited to tumor regions. This characteristic makes 
macrophages particularly attractive as a delivery vehicle to access solid tumors, which is normally 
difficult to reach by conventional targeting strategies. This immune cell-based delivery strategy has 
prolonged circulation time and excellent biocompatibility. I have created a strategy to engineer 
macrophages with the catalytic ability to activate prodrugs, that can trigger unlimited payload 
release with controlled kinetics and excellent targeting efficacy. In this study, I engineered 
macrophages as a delivery vehicle for nanozymes. These nanozymes can activate a prodrug by a 
bioorthogonal cleavage reaction in the cellular environment. By virtue of selective bioorthogonal 
chemical activation, I facilitated controlled release of drug molecules selectively at the targeted site 
reducing the systemic toxicity of the conventional therapy. The efficacy of engineered macrophages 
was tested in a coculture model with cancer cells. Significant cell toxicity was achieved even at the 
lowest concentration of the prodrug administered. This strategy combines targeting ability of cell-
based drug delivery with bio-orthogonal activation of chemotherapeutic prodrug, providing an 
approach for next generation drug delivery systems. 
In Chapter 4, I engineered nanozymes to target bacterial biofilms. Early detection of 
biofilms is crucial for limiting infection-based damage. Imaging these biofilms is challenging: 
conventional imaging agents are unable to penetrate the dense matrix of the biofilm, and many 
imaging agents are susceptible to false positive/negative responses due to phenotypical mutations 
of the constituent microbes. I developed a pH-responsive nanozyme, that are selectively uptaken 
by the acidic microenvironment of biofilm. These nanozymes generate imaging agents through 




detection of biofilm-associated infections. The specificity of these nanozymes for imaging biofilms 
in complex biosystems was demonstrated using co-culture experiments. 
In Chapter 5, I have used an alternative strategy to improve the selectivity of the nanozymes 
to target bacterial biofilms. Controlled localization of bio-orthogonal catalysts at the diseased site 
is central to the potency of the therapy. Notably, Red Blood Cells (RBCs) have been utilized to 
transport cargo to the targeted site with high efficacy. Moreover, these RBC carriers are susceptible 
to hemolysis by bacterial toxins providing them intrinsic targeting ability to bacterial infections. 
Here, I have developed a versatile strategy by hitch-hiking bioorthogonal nanozymes on RBCs to 
combat bacterial infections. I used a library of nanoparticles embedded with TMCs (nanozymes) 
featuring diverse functional groups with different binding ability to RBCs. These nanozymes were 
electrostatically adsorbed on carrier Red Blood Cells, enabling them to selectively accumulate at 
the site of bacterial infection while avoiding non-specific uptake in macrophages. The RBC-
nanozymes could activate moxifloxacin antibiotics to eradicate pathogenic biofilms without 
harming non-virulent bacterial species.  This study shows that interactions at nano-bio interface 
can play a crucial role in integration of synthetic materials with naturally occurring systems, 
resulting in novel antimicrobial therapies. 
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CONTROL OF INTRA- VERSUS EXTRACELLULAR BIOORTHOGONAL 
CATALYSIS USING SURFACE-ENGINEERED NANOZYMES 
2.1 Introduction 
Bioorthogonal chemistry is an emerging tool for interrogating and modulating cellular 
bioprocesses, harnessing the toolkit of synthetic chemistry to perform transformations outside the 
capabilities of biological systems.1-5 Bioorthogonal catalysis extends this capability, providing a 
platform for the transformation of substrates that mimics the catalytic amplification provided by 
enzymes in biological reactions. Transition metal catalysts (TMCs) are highly efficient systems for 
bioorthogonal activation of prodrugs and profluorophores.6-11 However, maintaining activity while 
controlling the localization of these systems remains an important issue.12 
Spatial localization of therapeutics and imaging agents is central to their utility in 
biomedicine, with different applications requiring either intra- or extracellular localization. 
Intracellular activation of prodrugs provides direct access to intracellular machinery for therapeutic 
intervention.12- 18  In contrast, extracellular targeting is important for regulating cell-surface 
signaling pathways,19,20 as well as when using cell-impermeable substrates as prodrugs21,22 or when 
targeting necrotic areas in tumors.23-25  
Incorporation of TMCs into nanoparticle monolayers provides a versatile strategy for 
creation of bioorthogonal nanocatalyst ‘nanozymes’. In recent studies we have shown that the use 
of 2 nm AuNPs provides stabilization of the catalysts in a package of similar size to many enzymes 
(~8 nm),17,26 featuring high catalytic activity in complex cellular media. We hypothesized that 
surface engineering of these nanozymes could be used to dictate either extra- or intracellular 
catalysis, expanding the utility of this platform for biomedical applications.  We report here the use 
of surface functionalization to provide effective localization of nanozymes and their catalytic 




zwitterionic particles to limit catalysis to extracellular space.28,30 Specific localization of nanozyme 
activity was demonstrated through profluorophore activation and therapeutic activation was 
demonstrated through intra- and extracellular activation of a prodrug. We observed that cationic 
nanozymes demonstrate significantly higher therapeutic efficacy as compared to their zwitterionic 
counterparts. The enhanced therapeutic efficacy exhibited by cationic nanozymes can be attributed 
to the stronger impact of intracellular drug activation coupled with somewhat higher catalytic rate 
of cationic nanozymes. These findings provide us with a modular approach to control the 
therapeutic efficacy of the drug through controlled bio-orthogonal activation. Taken together, these 
studies demonstrate enhanced spatial control for TMC-mediated bioorthogonal catalysis.  
Figure 2.1. a) Schematic representation of nanoparticles, nanozymes, and chemical structures of 
ligands of cationic nanozymes (Pos-NZ) and zwitterionic nanozymes (Zw-NZ) b) Structures of the 
pro-fluorescent substrates rhodamine 110 derivative (PF1) and resorufin derivative (PF2) and 
fluorescent products (rhodamine 110 and resorufin) after allylcarbamate/carbonate cleavage by 
TMC c) Schematic representation of specific localization of nanozymes using surface functionality; 




2.2 Results and Discussions 
AuNP (2 nm core) scaffolds were functionalized with ligands featuring three crucial 
components: (1) a hydrophobic interior segment that encapsulates the lipophilic TMCs, (2) a 
tetraethylene glycol spacer to provide biocompatibility, and (3) a terminal interacting unit that 
dictates intra/extracellular nanozyme localization (Figure 1). Positively charged quaternary 
ammonium ligands were used to generate Pos-NPs that were used for intracellular localization due 
to their high level of cellular uptake. 31 , 32  Zw-NPs scaffolds functionalized with zwitterionic 
sulfobetaine moieties were used for extracellular localization based on their minimal cellular 
uptake.33 (Figure 2.1). Both particles were synthesized from pentanethiol capped 2 nm core AuNPs 
scaffolds using place-exchange reaction (synthesis and characterization of nanoparticles are 
described in supporting information, Figures 2.S1, 2.S2, 2.S4 and 2.S5).   
Nanozymes were generated by catalyst encapsulation in AuNP monolayer of Pos-NPs28 
and Zw-NPs,30 to generate cationic Pos-NZ and zwitterionic (neutral) Zw-NZ nanozymes, 
respectively (Figure 1a). In this procedure the catalyst [Cp*Ru(cod)Cl] (Cp*= 
pentamethylcyclopentadienyl, cod=1,5-cyclooctadiene)34 was dissolved in acetone and added into 
an aqueous solution of the corresponding AuNPs in 1:1 volumetric ratio. Slow evaporation of 
acetone followed by purification to remove excess catalyst (details are in materials and methods 
section) provided the desired nanozymes.  
Transmission electron microscopy (TEM) and dynamic light scattering (DLS) indicate no 
aggregation of nanozymes after encapsulation of TMCs (Table 2.S1 and Figures 2.S2-2.S4). The 
quantification of ruthenium catalysts encapsulated in the corresponding nanozymes was obtained 
using inductively coupled plasma mass spectrometry (ICP-MS, Table 2.S2), with similar 
encapsulation efficiency observed with the two particles: Pos-NZ (29 catalysts per AuNP) and Zw-




      
 
Figure 2.2. a) Normalized fluorescence intensity (fluorescence at time t divided by the initial 
fluorescence intensity) of pro-fluorophores PF1 and PF2 (1 µM) by nanozymes (400 nM), b) 
relative rates of activation of PF1 and PF2 by nanozymes. Activity of Pos-NZ (blue and green) and 
Zw-NZ (black and red) were determined in sodium phosphate buffer (5 mM, pH 7.4) for 1 h. 
Potential activation of PF1 and PF2 by nanoparticles (Pos-NPs and Zw-NPs) was probed as 
negative controls. The data are average of triplicates and the error bars indicate standard deviations.    
The catalytic activity of nanozymes Pos-NZ and Zw-NZ was quantified by monitoring the 
deallylation-mediated fluorogenesis of two pro-fluorophores; alloc-protected rhodamine 110 (PF1) 
and alloc-protected resorufin (PF2) (Figure 2.1). A linear increase of fluorescence was observed 
after introducing the nanozymes into the pro-fluorophore solutions (Figure 2.2a), indicating that 
the Ru catalysts maintain their catalytic activity after encapsulation. The relative rate of increase in 
fluorescence intensity was measured from the slopes of the normalized intensities (Figure 2.2b). In 
the presence of Pos-NZ and Zw-NZ, the slope for PF1 activation was increased by 177- and 75-
fold respectively, and for PF2 activation was increased by 51- and 30-fold respectively (Figure 2.2b) 
relative to PF1 and PF2 alone. AuNPs (Pos-NP and Zw-NP) incubated with dyes (PF1 and PF2) 
were used as negative controls, exhibiting no increase in the fluorescence intensity. Next, we further 
assessed the catalytic activity of nanozymes over longer timeframes. Nanozymes (Pos-NZ and Zw-




evidenced in the fluorophore activation studies (Figure 2.S6). Fluorophore conversion rates for PF1 
and PF2 with nanozymes were calculated and are reported in supporting information (Table 2.S3). 
We next investigated the selective cellular uptake of Zw-NZs and Pos-NZs in HeLa (Figure 
2.3a) and RAW 264.7 macrophage cells (Figure 2.3b) using ICP-MS. We observed that cells treated 
with Pos-NZs showed high content of Au, whereas cells treated with Zw-NZs showed minimal 
uptake of Au.30 The amount of Ru catalysts found inside the cells was also quantified with 
consistent results (Figure 2.3). We further assessed the nanozyme uptake in the cells for extended 
duration of 72 h and the results mirrored the trend for 24 h incubation of nanozymes (Figure 2.S7). 
Next, the catalytic activity of these nanozymes after 72 h in vitro incubation was assessed through 
pro-fluorophore activation using confocal microscopy (Figure 2.S8). The activation of pro-
fluorophores inside the cells after extended period of cell incubation indicates the long-term 
stability of nanozymes.  
 
Figure 2.3. Cellular uptake of nanoparticle and TMC in a) HeLa (20,000 cells/well) b) RAW 264.7 
(20,000 cells/well) after overnight incubation with Pos-NZ and Zw-NZ with increasing 
concentration.  The data are average of triplicates and the error bars indicate standard deviations.    
After establishing the differential uptake of the nanozymes in cell lines, we next 
investigated the ability of nanozymes to activate profluorophores inside and outside the cells. We 
chose two fluorophores with different emission wavelengths and different molecular polarities for 
better visualization of catalysis in extra- and intracellular environments (Figure 2.1c). Rhodamine 




permeability across the cell membrane.12, 35  Less cell-permeable resorufin derivative PF2 (red 
emitter) was chosen to visualize extracellular catalysis.36,37 Cells were treated with PF1 overnight, 
followed by multiple washings to remove non-absorbed PF1 molecules (Figures 2.4a, b, d). Fresh 
media containing Pos-NZ was added to the cells for 0.5 h (Figures 2.4b, d). Non-adhered Pos-NZs 
were washed away followed by addition of Zw-NZ and PF2 into the cells (Figure 2.4d). After 
incubation with nanozymes and substrates, the cells were observed under a confocal microscope. 
As expected, substrates PF1 and PF2 did not exhibit any fluorescence in absence of nanozymes 
(Figure 2.4a). Cells treated with only Pos-NZ and PF1 showed intracellular fluorescence (Figure 
2.4b), while only Zw-NZ and PF2 showed extracellular fluorescence (Figure 2.4c). In presence of 
both the nanozymes and profluorophores, the cells exhibited green fluorescence inside the cells and 
a bright red fluorescence outside the cells demonstrating the ability of the nanozyme-based 
bioorthogonal system to activate different profluorophores with controlled spatial localization 
(Figures 2.4d and 2.S9). Intra-extracellular activation of pro-fluorophore was further investigated 
by altering the incubation order of cells with reagents i.e., the cells were treated with Pos-NZ, 
followed by PF1, Zw-NZ and PF2. No difference was observed upon changing the order of 
incubation of the reactive components, indicating strong spatial control of the nanozymes (Figure 
2.S10a). As additional controls, cells treated with Pos-NZ and PF2 (Figure 2.S10b) and Zw-NZ 
and PF1 (Figure 2.S10c) were visualized under confocal microscope. No fluorescence was 





Figure 2.4. Schematic representation and confocal imaging of controlled spatial activation of PF1 
and PF2 by treatment with bioorthogonal nanozymes Pos-NZ and Zw-NZ, respectively in HeLa 
and macrophages (RAW 264.7) observing a) no activation of substrates in absence of nanozymes 
b) intracellular catalysis in presence of only Pos-NZ and PF1 c) extracellular catalysis in presence 
of only Zw-NZ and PF2 d) intra- and extracellular catalysis in presence of both the nanozymes and 
profluorophores. Nuclei were stained by Hoechst 33342. Scale bars, 25 µm. 
We next assessed the ability of nanozymes to selectively activate prodrugs inside and 
outside the cells as a measure for relevant therapeutic applications. For this study, allylcarbamate 
protected doxorubicin (pro-Dox) was chosen as a model prodrug due to the high clinical relevance 
of its counterpart drug in cancer chemotherapy (Figure 2.5a).38-41 The caged amine group blocks 
the pharmacophore, preventing cytotoxicity prior to activation (Figure 2.S11). Cell viability studies 
were performed on HeLa cells using nanozymes and prodrugs to assess activation capacity of 
nanozymes for prodrugs in physiologically relevant conditions (Figure 2.5).  
For cell viability studies, HeLa cells were incubated with nanozymes (50 and 100 nM) and 




methods section). Cells incubated with only pro-Dox and free Dox were used as negative and 
positive controls, respectively. Figure 2.5b shows that pro-Dox does not show toxicity to cells. The 
viability of prodrug-treated cells is substantially reduced in the presence of our nanozymes however, 
indicating the successful catalytic activation of the prodrug. Cells co-incubated with pro-Dox and 
Pos-NZ (100 nM) displayed significantly lower viability than cells co-incubated with pro-Dox and 
Zw-NZ (100 nM). As a control, cell-viability studies were also done after altering the order of 
intracellular nanozyme and prodrug and no significant difference was observed (Figure 2.S12), 
illustrating the modular nature of our approach. Notably, Pos-NZ dominates the therapeutic effect 
when used in combination with Zw-NZ. This phenomenon can be attributed to stronger toxicity of 
intracellularly activated drug molecules as compared to the drugs activated outside the cells. 
Additionally, Pos-NZ exhibits higher catalytic activity as compared to Zw-NZ (Figure 2.2), which 
further amplifies the difference in their therapeutic impact. However, the combined therapeutic 
effect of mixture of Pos-NZ and Zw-NZ is higher than their individual components owing to the 
simultaneous activation of the prodrug by both nanozymes, increasing the total amount of drug 
molecules activated. These results indicating, as one might expect, that the intracellular activation 
of pro-Dox provides higher therapeutic efficacy than does extracellular activation, demonstrating 
the role of intracellular nanozyme localization in dictating desired therapeutic activity.  
2.3 Conclusions 
In summary, we have demonstrated the use of engineered nanozymes to predictably 
localize bioorthogonal catalysis to either extra- or intracellular space. The nanozymes were 
fabricated by encapsulating TMCs in the hydrophobic core of these surface functionalized AuNPs. 
A cell penetrating cationic AuNP scaffold was used for intracellular catalysis and a ‘stealth’ 
zwitterionic scaffold was used to limit catalysis to outside the cells. The ability of these engineered 
nanozymes to spatially localize catalysis heralds their use for therapeutic applications such as site-




membrane-impermeable drugs. Additionally, this strategy provides a means for activation of 
imaging agents in intra- and extracellular domains for diagnostic applications, with amplification 
arising from the catalytic capabilities of the nanozyme platform.  Notably, TMCs must exhibit long-
term stability in the hydrophobic monolayer of nanoparticles to provide a stable catalytic machinery, 
while the substrates must easily transition to a hydrophilic analogue upon activation to generate an 
effective pair with the nanozymes for efficient catalysis. Taken together, these studies provide a 
promising strategy for spatially controlling TMC mediated bioorthogonal catalysis for diagnosis 
and therapeutic applications.  
2.4 Experimental methods 
2.4.1 Synthesis of AuNPs.  2 nm diameter gold nanoparticles were synthetized by the 
Brust-Schiffrin two-phase methodology using pentanethiol as the stabilizer; these clusters were 
purified with successive extractions with ethanol and acetone. A Murray place exchange reaction 
was carried out in dry DCM to functionalize the nanoparticles with each ligand.42,43 The monolayer-
protected nanoparticles were redispersed in water and the excesses of ligand/pentanethiol were 
removed by dialysis using a 10,000 MWCO snake-skin membrane. The final concentration was 
measured by UV spectroscopy on a Molecular Devices SpectraMax M2 at 506 nm according to the 
reported methodology. 
2.4.2 Catalyst encapsulation in AuNP monolayer: 1 mL acetone was used to dissolve 2 
mg of the catalyst [Cp*Ru(cod)Cl] and mixed with 1 mL aqueous solution of the corresponding 
AuNPs (20 µM). The organic phase was slowly evaporated from the mixture using a rotary 
evaporator. Excess catalysts were removed from solution by filtration (Millex-GP filter; 25 mm 
PES, pore Size: 0.22 µm). Further purifications were done by centrifugal filters (five times, 
Amicon® ultra 4, 10K). The amount of encapsulated catalysts in each AuNPs was measured by 




2.4.3 Nanozyme kinetics in Solution: Allylcarbamate protected rhodamine 110 (PF1, 
green) and allylcarbonate protected resorufin (PF2, red) were used as substrates to test the catalytic 
activity of Pos-NZ and Zw-NZ. A solution containing 400 nM nanozyme and 1 µM substrate was 
prepared in a 96-well plate. 1 µM substrate solutions alone were used as negative controls. The 
kinetic study was done by tracking the fluorescence intensity of PF1 (lex = 488 nm, lem = 521 nm) 
and PF2 (lex = 543 nm, lem = 590 nm) using a Molecular Devices SpectraMax M2 microplate 
reader.  
2.4.4 Cellular uptake of the nanozymes: 20k HeLa and RAW 264.7 cells/well were 
plated in a 24-well plate prior to the experiment. Next day, the cells were washed with PBS and 
incubated with Pos-NZ and Zw-NZ (100, 200 and 400 nM) in 10% serum-containing media for 24 
h, 48 h and 72 h at 37 °C. Subsequently, the cells were washed with PBS to remove any excess 
nanozymes and then subjected to lysis buffer. The lysed cells were then further processed for ICP-
MS analysis. Each experiment was comprised of 3 replicates.  
2.4.5 Confocal imaging of catalysis inside and outside the cells: HeLa cells and RAW 
264.7 cells were grown in cell culture flasks using Dulbecco’s modified Eagle medium with 10% 
fetal bovine serum, at 37 °C in a humidified atmosphere of 5% CO2. For confocal analysis, HeLa 
and RAW 264.7 cells were seeded at 200k in 2 mL 10% serum-containing media in the confocal 
dish 24 h before the experiment. During the experiment, cells were washed by PBS buffer three 
times and old media was replaced by substrate PF1 (100 µM) in serum-containing media, and the 
cells were incubated for 24 h and washed with PBS buffer three times. The Pos-NZs (200 nM) were 
then added to the cells and incubated for 0.5 h. The cells were washed with PBS three times to 
remove excess Pos-NZ. Then a serum-containing media with a freshly prepared mixture of Zw-
NZs (200 nM) and PF2 (100 µM) was added to the washed cells. Confocal microscopy images 
were obtained after 0.5 h on a Nikon A1 spectral detector confocal microscope (A1SP) using a 60x 




green channel, lex = 488 nm and lem = BP 505-530 nm; red channel, lex = 561 nm and lem = LP 
590 nm. Emission filters: BP, band pass; LP, high pass.  
2.4.6 Prodrug activation: HeLa cells were seeded at 10k in 0.2 mL per well in 96-well 
plates 24 h before the experiment. Cells were washed off and incubated with Pos-NZ (50 nM) in 
10% serum-containing media. After 24 h, cells were washed with PBS buffer three times and 
treated with Zw-NZ (50 nM) and pro-Dox at a concentration of 0.5, 1, 2, and 4 µM for 24 h. The 
cells were then completely washed off and 10% alamar blue in serum-containing media was added 
to each well (220 µL) and incubated further at 37°C for 2 h. Cell viability was then determined by 
measuring the fluorescence intensity at 570 nm using a SpectraMax M5 microplate 
spectrophotometer. Absorbance spectra of free DOX was studied indicating no signal at 570 nm 
(Figure 2.S13). 
2.5 Supplementary information 
2.5.1 Mass spectrometric characterization of ligand on NPs. Matrix assisted laser 
desorption/ionization mass spectroscopy (MALDI-MS) was performed to characterize the surface 
ligand on the Pos-NP and Zw-NP. A matrix stock solution of a-Cyano-4-hydroxycinnamic acid 
(a-CHCA) was prepared in 70% acetonitrile, 30% deionized (DI) water. A mixture of 1 µM AuNPs 
solution and the matrix was prepared in 1:1 volume ratio. 2 µL of this mixture was spotted to the 
sample carrier and was allowed to stand for a few minutes to evaporate the solvent. MALDI-MS 
analysis was performed on a Bruker Autoflex III mass spectrometer. The peaks at m/z 422 and 530 





Figure 2.5. MALDI-MS for Pos-NP and Zw-NP. 
2.5.2 DLS and TEM characterization of nanoparticles and nanozymes. Hydrodynamic 
diameter of the nanoparticles and nanozymes were measured by dynamic light scattering (DLS) in 
DI water using a Malvern Zetasizer Nano ZS instrument by using the measurement angle of 173° 
(backscatter). Data were analyzed by the “multiple narrow modes” (high resolution) based on non-
negative-least-squares (NNLS).  
 Table 2.1. The size of nanoparticles (Pos-NP and Zw-NP) and nanozymes (Pos-NZ and Zw-
NZ) obtained from DLS 
 
 
Figure 2.6. DLS measurements of a) Pos-NP and Pos-NZ and b) Zw-NP and Zw-NZ, depicting 
that the size of nanoparticles stays the same. NP and NZ represent before and after catalyst 
encapsulation respectively.  
Sample Size (nm) Sample Size (nm) 
Pos-NP 8.2 ± 2.1 Pos-NZ 9.1 ± 2.1 





Figure 2.7. DLS measurements of a) Pos-NZ and b) Zw-NZ upto 5 days after catalyst encapsulation 
showing no evidence of aggregation. 
2.5.3 Transmission Electron Microscopy (TEM). Images of samples were taken before 
(Pos-NP and Zw-NP) and after catalyst encapsulation (Pos-NZ and Zw-NZ). Samples were 
prepared by placing one drop of the desired solution (1 µM) onto a 300-mesh Cu grid-coated with 
carbon film. Then the samples were analyzed and photographed using JEOL CX-100 electron 
microscopy. DLS and TEM images showed that there is no aggregation or change of morphology 
before and after catalyst encapsulation. 
 
Figure 2.8. TEM images of nanoparticles before (Pos-NP and Zw-NP) and after (Pos-NZ and Zw-
NZ) encapsulation of TMCs. Scale bar = 20 nm 
2.5.4 Zeta Potential characterization of nanoparticles and nanozymes. Zeta potential 





Figure 2.9. Zeta potential of a) Pos-Np (17.8 ± 4.2) and b) Zw-NP (-5.7 ± 5.6) 
2.5.5 Synthesis of allyl carbamate/carbonate protected substrates. Allyl 
carbamate/carbonate protected substrates (PF1, PF2 and Pro-Dox) were prepared with slight 
variations of earlier reports:44,45 
2.5.5.1 PF1. To a 10 ml pear-shaped flask equipped with a magnetic stir bar, was added 
Rhodamine 110 (100 mg, 0.27 mmol, 1.00 eq) and pyridine (65 µL, 0.80 mmol, 3.00 eq, r = 0.98 
g/mL) in dry DMF (0.5 mL) and was cooled down at 0 oC. Then, the flask was purged with nitrogen. 
Finally, allyl chloroformate (57 µL, 0.53 mmol, 2.00 eq, r = 1.13 g/mL) was added dropwise to 
the reaction solution. The reaction was allowed to warm to room temperature and stirred overnight. 
Afterwards, the reaction mixture was diluted with ethyl acetate (20 mL) and the mixture was 
washed with aqueous hydrochloric acid (5%, 10 mL) and with aqueous sodium bicarbonate solution 
(saturated, 2×10 mL). The organic phase was then dried with Na2SO4, filtered, and concentrated to 
yield a yellow residue. Flash chromatography using 1:1 Hexanes/Ethyl Acetate was done to yield 
solid PF1 (40% yield). 1H NMR (400 MHz, DMSO-d6) 10.05 (s, 2H), 8.0 (d, 1H), 7.77 (t, 1H) 7.7 
(t, 1H), 7.55 (s, 2H), 7.24 (d, 1H), 7.14 (d, 2H), 6.69 (d, 2H), 5.8 (m, 2H), 5.35 (d, 2H), 5.22 (d, 




2.5.5.2 PF2. To a 100 mL round bottom flask equipped with a magnetic stir bar, was added 
Resorufin sodium salt (1.0 g, 4.25 mmol, 1.00 eq) and pyridine (0.69 ml, 8.50 mmol, 2.00 eq, r = 
0.98 g/mL) and were dissolved in dry DMF (5 mL) and cooled down at 0 oC. Then, the flask was 
purged with nitrogen. Finally, allyl chloroformate (0.48 ml, 4.46 mmol, 1.05 eq, ρ = 1.13 g/mL) 
was added dropwise to the reaction solution. Afterwards, the reaction was allowed to warm to room 
temperature and stirred overnight.  Afterwards, the reaction was diluted with ethyl acetate (50 mL) 
and the mixture was washed with aqueous hydrochloric acid (5%, 25 mL), aqueous sodium 
bicarbonate solution (saturated, 2×25 mL), and brine. The organic layer was dried with Na2SO4, 
filtered, and concentrated. Flash chromatography using 4:1 Hexanes/Ethyl Acetate gave solid PF2 
(70% yield). 1H NMR (400 MHz, CDCl3) 7.71 (d, 1H), 7.39 (d, 1H), 7.17 (d, 1H), 7.15 (d, 1H), 
7.13 (d, 1H), 6.79 (d, 1H), 6.25 (d, 1H), 5.95 (m, 1H), 5.4 (d, 1H), 5.3 (d, 1H), 4.7 (d, 2H).  
2.5.5.3 Pro-Dox. Doxorubicin (10 mg, 18.1 µmol, 1.00 eq) and triethylamine (5.75 µL, 
40.9 µmol, 4.00 eq) were dissolved in dry DMF (1 mL) and cooled down at 0o C. Then allyl 
chloroformate (19.2 µL, 18.1 µmol, 1.00 eq, r = 1.13 g/mL) was dropwise mixed with previous 
solution. The resulting mixture was allowed to warm to room temperature overnight. After 14 h it 
was diluted with ethyl acetate (25 mL) and the mixture was washed with aqueous hydrochloric acid 
(5%, 10 mL) and with aqueous sodium bicarbonate solution (saturated, 2×10 mL). The organic 
layer was dried with Na2SO4, filtered, and concentrated to yield a dark residue. Flash 
chromatography using 1:1 Hexanes/Ethyl Acetate gave Pro-Dox as a dark solid (69 % yield). 1H 
NMR (400 MHz, CDCl3) δ = 13.96 (s, 1H), 13.22 (s, 1H), 8.02 (d, 1H), 7.77 (t, 1H), 7.37 (d, 1H), 
5.71 (m, 1H), 5.49 (d, 3.9, 1H), 5.28 (s, 1H), 5.16 (d, 1H), 4.94 (m, 2H), 4.74 (m, 2H),  4.50 (s, 
1H), 4.12 (q, 1H), 4.06 (s, 3H), 3.76 (d, 2H), 3.65 (d, 1H), 3.26 (m, 1H), 3.02 - 2.96 (m, 2H), 2.41 
(s, 1H), 2.31 (d, 1H), 2.15 (m, 1H), 1.87 (m, 2H), 1.75 (m, 1H), 1.27 (d, 3H). 
2.5.5.4 Quantification of catalyst per AuNP using ICP-MS characterization. ICP-MS 




197Au and 101Ru. Operating conditions were as follows: nebulizer flow rate: 0.95 L/min; rf power: 
1600 W; plasma Ar flow rate: 18 L/min; dwell time: 50 ms. A series of solutions with gold and 
ruthenium (concentration: 0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) were prepared for drawing the 
calibration curve. Nanozyme solutions were diluted in water to 200 nM. 10 µL sample solution was 
transferred to 15 mL centrifuge tubes. 0.5 mL of fresh aqua regia was added to each sample 
including the standard samples and was diluted to 10 mL with DI water.  
Table 2.2. Gold (Au) and ruthenium (Ru) amount in the nanozymes using ICP-MS 
measurement. The Ru/AuNP represents number of catalysts encapsulated per AuNP. 
 Au(ng) Ru(ng) Ru(ng)/AuNP(pmol) Ru/AuNP 
Pos-NZ 228.5 10.0 2.3 28.9 
232.6 9.9 2.7 
231.0 11.1 2.4 
Zw-NZ 229.5 10.8 2.2 24.2 
231.3 11.7 2.5 
231.8 12.2 2.7 
 
2.5.6 Nanozyme kinetics in solution. Allylcarbamate protected rhodamine 110 (PF1, 
green) and allylcarbonate protected resorufin (PF2, red) were used as substrates to test the catalytic 
activity of Pos-NZ and Zw-NZ. A solution containing 400 nM nanozyme and 1 µM substrate was 
prepared in a 96-well plate. 1 µM substrate solutions alone were used as negative controls. The 
kinetic study was done by tracking the fluorescence intensity of PF1 (lex = 488 nm, lem = 521 nm) 
and PF2 (lex = 543 nm, lem = 590 nm) using a Molecular Devices SpectraMax M2 microplate 





Figure 2.10. Normalized fluorescence intensity (fluorescence at time t divided by the initial 
fluorescence intensity) of pro-fluorophores PF1 and PF2 (1 µM) by nanozymes (400 nM). Activity 
of Pos-NZ (blue and green) and Zw-NZ (black and red) were determined in sodium phosphate 
buffer (5 mM, pH 7.4) for 72 h. Activation of PF1 and PF2 by nanoparticles (Pos-NPs and Zw-
NPs) were used as controls. The data are average of triplicates and the error bars indicate standard 
deviations.   
Fluorophore conversion rate was calculated using the calibration curve slope of Rhodamine 
110 (1900 a.u./µM) for PF1 and Resorufin (4125 a.u./µM) for PF2. 
Table 2.3. Fluorophore conversion rate per µM of nanozyme for PF1 and PF2. 
Nanozyme PF1 conversion rate x 10-3 (µM.S-1) 
Pos-NZ 2.5 ± 0.2 
Zw-NZ 0.9 ± 0.2 
Nanozyme PF2 conversion rate x 10-3 (µM.S-1) 
Pos-NZ 2.2 ± 0.2 
Zw-NZ 0.9 ± 0.2 
2.5.7 In-vitro stability of nanozymes in serum containing media. HeLa cells were seeded 
at 20,000 in 0.2 ml per well in 96-well plates 24 h before the experiment. Next day, the cells were 
washed with PBS and incubated with Pos-NZ and Zw-NZ (100, 200 and 400 nM) in 10% serum-




(3 times) and then subjected to lysis buffer. The lysed cells were then further processed for ICP-
MS analysis. Each experiment was comprised of 3 replicates.  
 
Figure 2.11. Cellular uptake of a) Au (ng/well) and b) Ru (ng/well) in HeLa (20,000 cells/well) 
after 24 h, 48 h and 72 h incubation with Pos-NZ and Zw-NZ with increasing concentration.  The 
data are average of triplicates and the error bars indicate standard deviations. 
Next, the catalytic activity of the nanozymes through profluorophore activation was 
assessed using confocal microscopy upto 72 h (3 days). HeLa cells were seeded at 200k in 2 mL 
10% serum-containing media in the confocal dish and treated with Pos-NZ (200 nM). After 24 h, 
48 h and 72 h incubation with Pos-NZ, cells were washed by PBS buffer three times and old media 
was replaced by PF1 (100 µM). After 24 h incubation with PF1, confocal imaging was obtained on 
Nikon A1 spectral detector confocal microscope (A1SP) using 60x objective. The settings of the 
confocal microscope were as follows (unless otherwise specified): green channel, lex = 488 nm and 
lem = BP 505-530 nm. Emission filters: BP, band pass; LP, high pass.  
 
Figure 2.12. Confocal images of activation of PF1 in HeLa cells after 24, 48 and 72 h incubation 
of Pos-NZ. The scale bars are 25 µm.  
2.5.8 Confocal imaging experiments to visualize intra-extracellular catalysis on 




modified Eagle medium with 10% fetal bovine serum, at 37 °C in a humidified atmosphere of 5% 
CO2. For confocal analysis, HeLa and RAW 264.7 cells were seeded at 200k in 2 mL 10% serum-
containing media in the confocal dish 24 h before the experiment. During the experiment, cells 
were washed by PBS buffer three times and old media was replaced by substrate PF1 (100 µM) in 
serum-containing media, and the cells were incubated for 24 h followed by washing with PBS 
buffer three times. The Pos-NZs (200 nM) and Hoechst nuclear stain were then added to the cells 
and incubated for 0.5 h. The cells were washed with PBS three times to remove excess Pos-NZ. 
Then PBS with a mixture of Zw-NZs (200 nM) and PF2 (100  M) was added to the washed cells. 
Confocal microscopy images were obtained after 0.5 h on Nikon A1 spectral detector confocal 
microscope (A1SP) using 60x objective. The settings of the confocal microscope were as follows 
(unless otherwise specified): green channel, lex = 488 nm and lem = BP 505-530 nm; red channel, 
lex = 543 nm and lem = LP 590 nm. Emission filters: BP, band pass; LP, high pass.  
 
Figure 2.13. Confocal images of HeLa cells and macrophage cells (RAW 264.7) a) incubated with 
PF1 and PF2 in absence of nanozymes indicating that no fluorescence is observed in presence of 
the pro-fluorophore alone, b) intracellular activation of rhodamine derivative (RHD 110) by Pos-
NZ, c) extracellular activation of resorufin derivative by Zw-NZ, d) simultaneous intra and 
extracellular activation in presence of Pos-NZ and Zw-NZ respectively. Nuclei were stained by 




2.5.9 Intra-extracellular imaging independent of the order of incubation of nanozyme 
and profluorophore. HeLa cells were seeded at 200k in 2 mL 10% serum-containing media in the 
confocal dish 24 h before the experiment. During the experiment, old media was replaced by Pos-
NZ (200 nM) in serum-containing media, and the cells were incubated for 0.5 h followed by 
washing with PBS buffer three times to remove the excess Pos-NZ. The PF1 (100 µM) was then 
added to the cells and incubated for 24 h. The cells were washed with PBS three times. Then, a 
mixture of Zw-NZs (200 nM) and PF2 (100 µM) in PBS and Hoechst nuclear stain was added to 
the cells. Confocal microscopy images were obtained after 0.5 h on Nikon A1 spectral detector 
confocal microscope (A1SP) using 60x objective. The settings of the confocal microscope were as 
follows (unless otherwise specified): green channel, lex = 488 nm and lem = BP 505-530 nm; red 
channel, lex = 561 nm and lem = LP 590 nm. Emission filters: BP, band pass; LP, high pass.  
 
Figure 2.14. Confocal images of HeLa cells a) intra-extracellular fluorescence after altering the 
order of incubation, as additional controls HeLa cells were b) incubated with Pos-NZ followed by 
PF2, and c) incubated with Zw-NZ and PF1. Nuclei were stained by Hoechst 33342. The scale bars 
are 25 µm.  
2.5.10 Cytotoxicity measurements of Pro-Dox and free Dox. HeLa cells were seeded at 
10,000 in 0.2 mL per well in 96-well plates 24 h before the experiment. Cells were washed with 
PBS buffer and then treated with 10 different concentrations ranging from 10 nM to 20 µM of free 
Dox and pro-Dox in triplicate. After 24 h of incubation, the cells were then completely washed off 
with PBS buffer three times, and 10% alamar Blue in serum-containing media was added to each 




measuring the fluorescence intensity at 570 nm using a SpectraMax M5 microplate 
spectrophotometer.  
 
Figure 2.15. Viability of cells treated with free-Dox and pro-Dox at various concentrations, 
showing a nice therapeutic window between the two. 
2.5.11 Intracellular therapeutic activation independent of the order of incubation of 
nanozyme and prodrug. HeLa cells were seeded at 10k in 0.2 mL per well in 96-well plates 24 h 
before the experiment. Cells were washed off and incubated with Pro-Dox at a concentration of 0.5, 
1, 2, and 4 µM. After 24 h, cells were washed with PBS buffer three times and treated with Pos-
NZ (100 nM) and Pos-NP (100 nM) in 10% serum-containing media for 24 h. The cells were then 
completely washed off and 10% alamar blue in serum-containing media was added to each well 
(220 µL) and incubated further at 37°C for 2 h. Cell viability was then determined by measuring 
the fluorescence intensity at 570 nm using a SpectraMax M5 microplate spectrophotometer.  
 
Figure 2.16. Cell viability after altering the order of incubation of Pos-NZ and pro-Dox. Cells 
treated with Pos-NPs and pro-Dox was used as an additional control. The data are average of 




2.5.12 Absorbance spectra of free Dox. We studied the absorbance spectra of Dox at the 
maximum concentration used in the experiment (4 µM) using a UV-VIS reader. We observed 
maximum absorbance at 490 nm, but no signal was observed at 570 nm.46 
     
Figure 2.17. Absorbance spectrum of Dox (4 µM) in sodium phosphate buffer (5 mM, pH 7.4). 
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MACROPHAGE-ENCAPSULATED BIOORTHOGONAL NANOZYMES: 
TOOLS FOR TARGETED CANCER THERAPY 
3.1 Introduction 
Targeted drug delivery has emerged as a prominent strategy for avoiding widespread 
toxicity typically associated with conventional cancer chemotherapies. The successful application 
of targeting has been shown to result in improved survival time and patient quality of life.1-3 
Macrophages are innate immune cells that are inherently attracted to specific tissue environments, 
including hypoxic, ischemic, and necrotic areas associated with tumors and their cores. 4 - 6 
Concurrently, many cancers secrete macrophage chemoattractants, whose gradients the cells 
migrate across, resulting in active recruitment to cancerous regions.7,8 This characteristic makes 
macrophages particularly attractive as cell-based delivery vehicles for accessing solid tumors, 
which are normally difficult to reach by using conventional targeting strategies.9,10  
Previous approaches have utilized macrophages loaded with nanoparticle-drug conjugates 
or free drugs for anti-cancer therapeutic delivery.11,12 In several cases, the cell-mediated delivery 
resulted in greater efficacy than free materials, and reduced off-target toxicity.13,14 However, the 
direct loading approach is hindered by the ceiling for amount of loadable payload and lack of 
controlled release. Cells are limited in the amount of drug they can carry, and there are no means 
to regulate the rate, extent, and site of discharge. The loaded cytotoxic drugs can also affect or kill 
the carrier cell prior to reaching the desired target site. To a certain extent, these issues can be 
addressed by utilizing macrophages bearing stimuli-responsive nanoparticles, which control the 
release of therapeutics.15,16 In these approaches, external stimuli such as thermal energy, light, or 
ultrasound can be used to trigger nanoparticles’ release of drug molecules, specifically at the tumor 
site. While this type of strategy is promising, limited therapeutic loading remains a hurdle. Also, 




surrounding healthy tissues is a concern. Thus, an alternative means is needed to make 
macrophage-mediated drug delivery clinically successful. 
Bioorthogonal catalysis17,18 has the potential to overcome limitations associated with 
payload loading of and release from macrophages and other cell-based delivery agents. 
Internalized catalysts can be transported by cells to the desired tissue/organ, where they 
continuously generate active therapeutics from inactive prodrugs at the targeted location. Prodrugs 
are protected drug molecules that remain nontoxic until activated by a stimulus.19,20 In our study, 
we engineered macrophages as a delivery vehicle for transition metal catalyst (TMC)-bearing gold 
nanoparticles (AuNPs), or nanozymes (NZs). These catalysts, which are embedded in the AuNPs, 
can activate a profluorophore/prodrug via bioorthogonal cleavage reaction in the cellular 
environment, as reported in previous studies.21-24 Here, following encapsulation into macrophages, 
minimal nanozyme release from the cells was observed, even after a prolonged incubation period. 
We tested the efficacy of engineered macrophages (RAW_NZ) in a co-culture model with HeLa 
(human cervical cancer) cells. Significant cancer cell toxicity was achieved in the presence of 
nanozyme-bearing macrophages, even at the lowest concentration of the prodrug administered. In 
addition to cancer cell killing abilities, it is important to retain the macrophages’ chemotactic 
properties following nanozyme internalization, which is critical for the engineered cells to reach 
the targeted tumor site. For this reason, we assessed the migratory behavior of engineered versus 
non-modified macrophages towards the Colony Stimulating Factor-1 (CSF) chemoattractant.25 In 
chemotaxis assays, both cell populations exhibited similar behaviors. Our strategy here combines 
the targeting ability of cell-based drug delivery with bio-orthogonal activation of a 





Figure 3.1. Schematic representation of macrophage mediated delivery of bioorthogonal 
nanozymes (NZs) for prodrug activation selectively at tumor cells.  
3.2 Results and discussion 
In this study, we designed 2 nm AuNPs functionalized with a ligand containing a cationic 
terminal group (TTMA) to facilitate a high degree of uptake by the negatively charged cell 
membrane.26-29 The AuNP ligand monolayer contains a crucial hydrophobic alkane chain for 
catalyst encapsulation and a tetra(ethylene glycol) spacer to provide biocompatibility (Figure 3.1). 
These particles were synthesized from pentane-thiol capped 2 nm core AuNPs using a place 
exchange reaction (synthesis and characterization of NPs is described in supporting information, 
Figures 3.S1, 3.S2).30  Nanozymes were generated by immobilizing hydrophobic palladium TMC 
(1,1′ bis(diphenylphosphino) ferrocene)palladium(II)dichloride31-33 in the hydrophobic portion of 
AuNP monolayer.21 The catalyst was dissolved in acetone and added into an aqueous solution of 
AuNPs in a 1:1 ratio by volume. Acetone was evaporated slowly and any excess catalyst was 
filtered away to provide the desired nanozyme (details of nanozyme preparation and 
characterization are in supporting information). There was no aggregation observed before or after 
encapsulation of TMCs, as confirmed by dynamic light scattering (DLS) (Table 3.S1 and Figure 
3.S3) and transmission electron microscopy (TEM) (Figure 3.S4). Quantification by inductively 
coupled plasma mass spectrometry (ICP-MS) (Table 3.S2) indicated that on average, 37 ± 1 




NZs were internalized by macrophages (RAW 264.7) in vitro to generate RAW_NZ 
(Figure 3.1) (details in supporting information). The quantification by ICP-MS showed that both 
Au (Figure 3.2a) and Pd (Figure 3.2b) content increased concommittantly with NZ concentration. 
We also assessed the amounts of Au and Pd in macrophages following prolonged incubation 
periods of 48 h and 72 h. These results were similar to the those observed for the 24 h incubation 
time (Figure 3.2), establishing the long term retention of NZs inside macrophages. 
 
Figure 3.2. Cellular uptake of a) Au (ng/well) and b) Pd (ng/well) in macrophages (RAW 264.7 
at 20,000 cells/well) after 24 h, 48 h and 72 h incubation with NZs with increasing concentration. 
The data shown are averages of triplicates; error bars indicate standard deviations. 
We next investigated the effects of nanozyme internalization on macrophage responses to 
chemotactic signals, which are critical to their employment for tumor targeting.[9a] Colony 
Stimulating Factor-1 (CSF-1) was used as the chemoattractant, and migration was evaluated by 
transwell membrane assay (Figure 3.3). We compared the ability of macrophages with NZ 
(RAW_NZ) and without NZ (RAW 264.7) to traffick through a membrane in response to CSF-1. 
To visualize and quantify the migrated cells, macrophages were stained with crystal violet at the 
conclusion of the experiment (detailed procedure is described in supporting information). No 
significant difference was observed in the behaviour of macrophages with and without NZs as 
observed under wide-field fluorescence microscope (Figure 3.3a) and after quantification (Figure 





Figure 3.3. Chemotaxis capabilities are retained by RAW_NZ as determined by transwell 
membrane assay. a) Confocal imaging of migrated macrophages with NZs (RAW_NZ) and 
without NZs (RAW 264.7) in presence and absence of chemoattractant Colony-Stimulating 
Factor-1 (CSF-1). All cells were stained with crystal violet to facilitate detection. Scale bar = 100 
µm. b)  Quantification of migrated RAW 264.7 cells and RAW_NZ in presence and absence of 
CSF-1. Nine panels of cells were counted per treatment (n = 9, from three biological replicates, 
represented by differently colored diamonds). Box constitutes the interquartile range (25th to 75th 
percentile), the intersecting line designates the median, the small square in the center represents 
the mean, and the bottom and top whiskers specify the 5th and 95th percentiles, respectively. 
After establishing the high stability of RAW_NZs and their ability to retain inherent 
chemotaxis capabilities of macrophages, we next investigated their therapeutic activation in a co-
culture model with HeLa cells (Figure 3.4). For this study, propargyl protected 5-fluorouracil (pro-
5FU) was chosen as a model prodrug (Figure 3.4a), due to the broad application of its active 
counterpart (5FU).34,35 The caged propargyl group blocks the active site of 5FU, reducing its 
cytotoxicity before activation by the NZs (Figure 3.S5). For the co-culture experiment, RAW_NZ 
cells were seeded on a glass slide, which was then immersed in a well seeded with HeLa cells 
(Figure 3.4b). The co-incubated cell lines were incubated with prodrug at different concentrations, 




slide with RAW_NZ was removed before performing alamar blue assay separately on HeLa cells 
and macrophages (the detailed experimental procedure is provided in supporting information). In 
the presence of RAW_NZ, the viability of both HeLa (Figure 3.4c) and RAW 264.7 (Figure 3.S6) 
cells was substantially reduced with increasing concentrations of prodrug, indicating successful 
therapeutic activation by NZ. HeLa cells that received increasing concentrations of prodrug, but 
were not co-cultured with RAW_NZ did not show any reduction in cell viability, indicating 
successful protection of the active site of 5FU (Figure 3.4c). The same trend was mirrored in the 
case of RAW 264.7 cells that were not modified with NZs (Figure 3.S6). Our  findings illustrate 
that the prodrug activation occurred only in the presence of NZs, not with macrophages alone. 
While diminished viability of RAW 264.7 cells was observed, this only occurred in treatments 
where NZ and prodrug were both present. In therapeutic settings, carrier cell death is not an issue 
so long as it occurs after the target tissue has been reached. Both HeLa (Figure 3.4) and RAW 
264.7 (Figure 3.S6) cells were treated with 5FU as a positive control.  
Figure 3.4. a) Pro-5FU activation by RAW_NZ. B) Graphical scheme of co-culture experiment 
to evaluate therapeutic efficacy of RAW_NZ in HeLa cells. c) Viability of HeLa cells after pro-
5FU (prodrug) activation by RAW_NZ in the co-culture experiment. The data are average of 




In order to expand upon these findings, we determined the effects of the RAW_NZ/Pro-
5FU treatments in situ. Here, we co-cultured RAW_NZ with green fluorescent protein (GFP) 
expressing HeLa cells (GFP-HeLa) and separately, U2OS cells (GFP-U2OS). The green 
fluorescence of both GFP-HeLa cells and GFP-U2OS cells was greatly reduced with increasing 
concentration of prodrug (Figure 3.S7), due to increased cytotoxicity resulting from  by active 
drug molecules, as observed by confocal microscopy.  
 
Figure 3.5. Co-culture experiment of RAW_NZ with a) GFP_HeLa cells and b) GFP_U2OS cells 
to demonstrate the reduction of GFP fluorescence as a result of pro-5FU activation by RAW_NZ. 
Scale bar = 15 µm.  
3.3 Conclusions 
In summary, we have developed a macrophage-mediated delivery platform for 
bioorthogonal nanozymes to generate therapeutic molecules at desired sites. Macrophages bearing 
internalized nanozymes demonstrated high therapeutic activation in a co-culture model with 
cancer cells. The macrophages retained the nanozymes for prolonged incubation periods and also 
demonstrated similar chemotactic behaviours to their non-modified counterparts, illustrating their 
potential for use in in vivo applications. By using nanozymes to activate pharmacological 




Considering their enhanced ability for targeting, this platform holds a strong advantage against 
current chemotherapy and cell-based therapeutic delivery techniques. Future studies will explore 
the use of this platform for specific drug activation in in vivo models.  
3.4 Experimental methods 
3.4.1 Nanoparticles synthesis. 2 nm diameter gold nanoparticles were synthetized by the 
Brust-Schiffrin two-phase methodology36 using pentanethiol as the stabilizer; these clusters were 
purified with successive extractions with ethanol and acetone. A Murray place exchange reaction37 
was carried out in dry DCM to functionalize the nanoparticles with each ligand. 38 , 39  The 
monolayer-protected nanoparticles were redispersed in water and the excesses of 
ligand/pentanethiol were removed by dialysis using a 10,000 MWCO snake-skin membrane. The 
final concentration was measured by UV spectroscopy on a Molecular Devices SpectraMax M2 
at 506 nm. 
3.4.2 Mammalian cell culture. All mammalian cells were grown in T75 cell culture 
flasks using standard growth media (DMEM supplemented with 10% FBS and 1% Pen-Strep) 
under physiological conditions (37 °C in a humidified atmosphere of 5% CO2). Once the cells 
were at sufficient density, they were washed with phosphate-buffered saline (PBS) three times 
followed by 0.05% trypsinization. The trypsinized cells were centrifuged and resuspended in fresh 
culture media. 10 µL of cell solution was mixed with trypan blue in 1:1 volume ratio and was 
counted by a hemocytometer. The cell solutions were diluted in the same media to attain the 
desired cell concentration for subsequent experiments. 
3.4.3 Preparation of engineered macrophages (RAW_NZ). Macrophages (RAW 264.7) 
were seeded at a concentration of 20,000 cells/well in a 24 well plate, and allowed to attach 
overnight. The following day, cells were washed three times with PBS to remove any dead cells. 




incubated for 24 h. After, the cells were thoroughly washed by PBS three times to remove any 
excess NZ to provide RAW_NZ. RAW_NZ was trypsinized depending on experiment to follow. 
3.4.4 Chemotaxis/Boyden Chamber assay procedure. Cell migration towards Colony 
Stimulating Factor 1 (CSF-1) was investigated by a Boyden Chamber Assay following a 
previously described protocol.40,41 Briefly, a transwell membrane with 8 µm pore size was coated 
with 10 µg/mL fibronectin. After 4 hours, the excess fibronectin was rinsed with PBS and left to 
dry for overnight. The next day, designated wells of a 24 well plate received 650 µL serum-free 
growth media supplemented with 40 ng/mL rCSF-1; control wells received serum-free growth 
media only. The fibronectin coated inserts were then placed onto the wells. 100 µL of RAW-NZ 
(100,000 cells/well) solution was added into each insert and incubated for 12 h at 37 °C and 5% 
CO2. Non-migratory cells were removed with a Q-tip and migratory cells at the bottoms of the 
inserts were fixed in 4% formaldehyde and stained with a 0.1% crystal violet solution in 25% 
methanol. Membranes were removed precisely, mounted onto cover-glass, and visualized under a 
Zeiss Axio Observer Z1 with an Axio Cam 506 Color attachment under a 20× objective lens. The 
cells were counted from three random, non-overlapping fields of view per membrane, with three 
membranes per condition (n = 3*3 = 9). Box and whisker plots were generated using OriginPro 
2017. 
3.4.5 Co-culture experiment of RAW_NZ with HeLa cells. Glass slides were coated 
with poly-lysine solution followed by washing with PBS. The slides were dried overnight. Each 
of the dry glass slides was placed onto each well of 6-well plates. Macrophages (RAW 264.7) 
(100k/well) in standard growth media were seeded in designated wells with glass slides. 3 mL of 
this media was used for each well to ensure that the glass slides remained immersed fully in the 
solution. The cells were treated with 100 nM NZs for the wells designated as RAW_NZ. In parallel, 
HeLa cells (100,000/well) were seeded in separate 6 well plates. The plates were stored under 




adding fresh standard growth media. The glass slides coated with RAW 264.7/ RAW_NZ were 
thoroughly washed with PBS to remove any non-adhered cells and/or excess NZ. The slides coated 
with RAW 264.7/RAW_NZ were then removed carefully with a tweezer from their designated 
wells and placed atop the HeLa cells for coculture, so that both HeLa cells and RAW 
264.7/RAW_NZ remained in the same solution. For control experiments with only HeLa cells, 
blank glass slides were placed on top of the cells. For control experiments with only RAW 264.7 
cells, the slides coated with RAW 264.7 cells were placed in wells with only media. The cells 
were incubated with prodrug/drug for 24 h followed by washing three times with PBS. The glass 
slides were removed and placed in separate 6-well plates. All wells (with cells now separated) 
were thoroughly washed with PBS three times. Alamar blue assay was performed separately for 
HeLa and RAW 264.7 cells. 
3.4.6 Co-culture experiment of RAW_NZ with GFP expressing HeLa cells 
(GFP_HeLa) and U2OS cells (GFP_U2OS). RAW 264.7 cells were seeded at a concentration 
of 100,000 cells/2 mL in confocal dishes. The cells were incubated with 100 nM NZ solution for 
24 h followed by washing three times with PBS. GFP_HeLa/GFP_U2OS cells were added to the 
dishes at a concentration of 100,000 cells/dish to perform coculture of RAW_NZ+GFP_HeLa and 
RAW_NZ+GFP_U2OS, respectively. After 24 hours, the co-cultured cells were washed three 
times with PBS and incubated with prodrug for 24 h. The media in the confocal dishes was 
replaced with PBS before imaging. Confocal microscopy images were obtained on Nikon A1 
spectral detector confocal microscope (A1SP) using a 60x objective. The settings of the confocal 
microscope were as follows: green channel, lex = 488 nm and lem = BP 505-530 nm; emission 
filters: BP, band pass; LP, high pass. 
3.5 Supplementary information 
3.5.1 Mass spectrometric characterization of ligand on NPs. The surface ligand was 




stock solution of matrix a-Cyano-4-hydroxycinnamic acid (a-CHCA) was prepared in a mixture 
of 70% acetonitrile and 30% deionized water. AuNPs were diluted in deionized water to a final 
concentration of 1 μM followed by addition to the matrix solution in a 1:1 volume ratio. 2 μL of 
this mixture was spotted on the sample carrier and allowed to dry. MALDI-MS analysis was 
performed using a Bruker Autoflex III mass spectrometer. A peak at m/z 422.637 was detected 
for TTMA AuNPs.  
 
Figure 3.6. MALDI-MS for TTMA AuNPs. 
3.5.2 Zeta Potential characterization of AuNPs. Hydrodynamic diameter of the 
nanoparticles and nanozymes were measured by dynamic light scattering (DLS) in DI water using 
a Malvern Zetasizer Nano ZS instrument by using the measurement angle of 173° (backscatter). 
Data were analyzed by the “multiple narrow modes” (high resolution) based on non-negative-
least-squares (NNLS).  




3.5.3 DLS and TEM characterization of AuNP and NZ. Hydrodynamic diameter of 
AuNPs and NZs were measured by dynamic light scattering (DLS) in DI water using a Malvern 
Zetasizer Nano ZS instrument by using a measurement angle of 173° (backscatter). Data were 
analyzed by the “multiple narrow modes” (high resolution) based on non-negative-least-squares 
(NNLS). 
 
Figure 3.8. DLS measurements of AuNPs and NZs, indicating no aggregation before or after 
catalyst encapsulation. 
Transmission Electron Microscopy (TEM) imaging samples were prepared by placing a 
droplet of AuNP and NZ solution of 1 µM onto a 300-mesh Cu-grid coated with carbon film. The 
samples were analyzed using a JEOL CX-100 electron microscope. These characterization data 
indicated that there was no aggregation before or after catalyst encapsulation.  
 
Figure 3.9. TEM images of a) AuNPs and b) NZs. Scale bar = 100 nm 
3.5.4 Quantification of catalyst per AuNP using ICP-MS characterization. The ICP-




106Pd were measured under the standard mode. Operating conditions were: nebulizer flow rate: 
0.95 L/min; rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 50 ms. Standard gold 
and palladium solutions were prepared via serial dilutions (0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) for 
the calibration curve. It was found that 37 ± 1 catalysts were present per AuNP. 
Table 3.1. Quantification of encapsulated catalysts in the 2 nm TTMA-AuNP 
 Au(ng) Pd(ng) Pd(ng)/AuNP(pmol) Pd/AuNP 
NZ 62.3 5.3 3.9 37 ± 1 
65.9 5.5 4 
63.2 5.5 4.1 
 
3.5.5 Cytotoxicity measurements of prodrug and drug. HeLa cells were seeded at a 
concentration of 10,000 cells/well in a 96 well plate overnight. The next day, the cells were treated 
with pro-5FU and 5FU at various concentrations for 24 h. After the incubation period, the cells 
were washed three times with PBS to remove dead cells and excess pro-5FU/5FU. 10% alamar 
blue in serum containing media was added to each well (220 µL) and incubated for 2 h further at 
37 °C and 5% CO2. Cell viability was then determined by measuring the fluorescence intensity at 
570 nm using a SpectraMax M5 microplate spectrophotometer. The cell viability results indicated 
the presence of a therapeutic window between the prodrug and the drug. 
 
Figure 3.10. Viability of cells treated with pro-5FU and 5FU at various concentrations as 





Figure 3.11. Viability of RAW 264.7 cells treated with pro-5FU and 5FU at various 
concentrations as determined by alamar blue assay. 
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CHARGE-SWITCHABLE NANOZYMES FOR BIOORTHOGONAL IMAGING 
OF BIOFILM-ASSOCIATED INFECTIONS  
4.1 Introduction 
Bacterial infections are serious threat to public health, causing > 2 million cases of illnesses 
and >23,000 deaths each year in U.S.1 The majority of human bacterial infections (~80%) are 
associated with biofilm formation on living tissues.2  Biofilms are three-dimensional bacterial 
communities where microbes reside in an extracellular polymeric substance (EPS) matrix, and are 
highly protected from exogenous agents. Biofilm-associated infections are responsible for a range 
of chronic diseases including endocarditis, osteomyelitis and implant dysfunction, and are key co-
morbity threats for other diseases such as cystic fibrosis.3 , 4  Currently, biofilm infections are 
typically diagnosed only after they have become systemic or have caused significant anatomical 
damage,5,6 highlighting the need for effective imaging tools. 
Current techniques for imaging bacteria use probes such as autologous white blood cells7, 
maltodextrin8 and dipicolylamine zinc (II).9  Although these systems are effective for imaging 
planktonic (dispersed) bacterial infections, only limited studies have been conducted on imaging 
of biofilm-associated infections.10-12 Other imaging modalities such as 67Ga-citrate and radiolabeled 
autologous white blood cells lack the spatial resolution required for surgical procedures such as 
debridement of infected tissue.6, 13  Most high resolution optical imaging approaches rely on 
fluorescent dyes conjugated to a biorecognition element, generating highly specific imaging probes 
that are susceptible to false responses due to phenotypic mutations of biofilm residing microbes.14,15 
Moreover, physical heterogeneity and complex biofilm architecture further complicates imaging of 
these highly refractory infections.16 In particular, the dense and amphiphilic nature of EPS matrix 




(NPs) have shown potential to penetrate biofilms19, however they currently lack the ability to 
intrinsically target these resilient infections.20,21 
Biofilms have inherently acidic microenvironments (pH 4.5-6.5) as a by-product of sugar 
fermentation caused by bacteria.22 For instance, pH in human dental biofilms often reaches below 
4.5 causing acidic dissolution of tooth enamel. 23  Similarly, cystic fibrosis (CF) pulmonary 
infections are associated with acidification of airways in CF patients.24 We hypothesized that pH-
responsive sulfonamide-functionalized gold nanoparticles (AuNPs)25 could be used to target this 
acidic environment. In this system, targeting of the biofilm is achieved through charge-switchable 
NPs that transition from zwitterionic (non-adhesive) to cationic (adhesive) at the pH values 
typically found in biofilms, providing a broad-spectrum recognition platform for bacteria with 
selectivity towards biofilms compared to healthy mammalian cells. Imaging of the biofilms is 
achieved by the embedded transition metal catalysts (TMCs) that activate the pro-fluorophores in 
situ inside the biofilms. These bioorthogonal ‘nanozymes’ provide an effective imaging system that 
selectively targets bacterial biofilms and provides amplified fluorescence signal output using 
bioorthogonal catalysis. This nanozyme platform was used to effectively image biofilms of 
different bacterial species with complete EPS matrix penetration, and to image biofilms in a 





Figure 4.1. a) Molecular structures of pH-switchable and control ligands on gold nanoparticles 
(AuNPs). b) Schematic representation showing selective targeting of biofilm infections using pH-
responsive nanoparticles and intrabiofilm fluorogenesis of profluorophores by transition metal 
catalysts (TMCs) embedded in the nanoparticle monolayers. 
4.2 Results and discussion 
Sensing was performed with 2nm AuNPs featuring terminal groups with distinct pKa 
values to selectively target the acidic microenvironment of biofilms.25 Alkoxyphenyl 
acylsulfonamide-functionalized NP1 features groups that are protonated under weakly acidic 
conditions (pKa ~ 6.5), consistent with normal biofilm pH. Acylsulfonamide-functionalized  NP2 
has slightly lower pKa (~4.5) than its aryl analog, providing a tool for measuring the lower extremes 
of biofilm pH.  Finally, NP3 features a sulfobetaine termini, providing a stable zwitterionic control 
for our studies (pKa < 1) (Figure 4.1 a).26,27 These particles were synthesized from pentane-thiol 




The nanozymes were generated through encapsulation of a ruthenium-based catalyst-
[Cp*Ru(cod)Cl] (Cp* = pentamethylcyclopentadienyl, cod = 1,5-cyclooctadiene) into the ligand 
monolayer of NP1-3 to generate the respective nanozymes (NZ1-3). 28  Transmission electron 
microscopy (TEM) images and dynamic light scattering data of NPs before and after encapsulation 
of catalysts show no signs of aggregation. Further size distribution studies for NZs were conducted 
at a range of pH (3.5-7.4) using DLS, demonstrating their stability even in the acidic conditions 
(Figure 4.S1, Figure 4.S2). The quantification of catalysts encapsulated was done using inductively 
coupled plasma mass spectrometry (ICP-MS), indicating that 24 ± 2 catalyst molecules were 
encapsulated per AuNP for NZ1-3. The catalysts encapsulated per AuNP were similar at different 
pH ranges (3.5-7.4), as validated using ICP-MS (Figure 4.S3).   
 
Figure 4.2. a) Catalysis of nanozymes with different chemical headgroups in neutral pH for 2 h at 
37 °C. b) ζ-Potential of NZ1−3 (1 μM) measured in the pH range of 3.5−7.4 is plotted against 
different pH values. Error bars represent standard deviations based on three independent 
measurements per pH value. c) Nanoparticle and catalyst diffusion into P. aeruginosa (CD-1006) 
biofilms after incubation for 1 hr in pH 7.4 media with NZ1−3 (400 nM), as measured by ICP-MS. 
d) Confocal images of biofilm incubated with nanozymes (1 h, 400 nM) followed by incubation 
with alloc-Rho (1 h, 100 μM); biofilm control is the negative control in the absence of nanozyme. 
e) Quantitative analysis of fluorescence intensity generated upon addition of different nanozymes. 
The catalytic activities of NZ1-3 were assessed in solution by deallylation of bis-N, N’-




fluorescence was similar (Figure 4.2a) for the NZ1-3 complexes, indicating similar catalytic 
activity for all NZs at physiological pH. Further, we tested the catalytic activity of NZ1 with varying 
pH (3.5-7.4), indicating no significant difference in the catalysis rate for the nanozyme (Figure 
4.S4).  
After establishing their catalytic activity in solution, we determined the pH dependence of 
the NZ’s surface charge by measuring their zeta potential. The surface charge of all three NZs (1-
3) were close to neutral at physiological pH (7.4), consistent with their zwitterionic structures. NZ 
(1-2) exhibited a sharp transition from neutral to overall positive charge at pH 6.5 and pH 4.5 
respectively, consistent with their respective pKa’s. As expected, NZ3 possessed near neutral 
charge even at highly acidic pH values as seen in Figure 4.2b and Figure 4.S2. Next, we performed 
NZ diffusion studies in biofilms using ICP-MS to investigate their ability to penetrate and 
accumulate inside biofilms. We observed that switchable NZ1 showed the highest diffusion into 
biofilms based on Au, with lesser amounts observed with NZ2 and NZ3 respectively (Figure 4.2c). 
This trend is mirrored in the Ru signal from the catalyst. This overall change to cationic surface 
charge of the pH-responsive NZs can play a crucial role in their ability to intrinsically target 
biofilms over the mammalian cells (Figure 4.S5). 
We then investigated the ability of NZs to image biofilms using confocal microscopy. We 
chose uropathogenic clinical isolate of P. aeruginosa (CD-1006) as a model strain for imaging 
studies due to their high prevalence in clinical biofilms.30,31 Imaging studies of biofilms were based 
on generation of fluorophore (Rhodamine 110) through deallylation of a non-fluorescent precursor 
as shown in Figure 4.1b. Catalytic activity of the NZs was probed inside the biofilms by incubating 
the NZs with biofilms for 1 h, followed by multiple washings to remove absorbed particles. Fresh 
media containing substrate was added following 1 h incubation and subsequent washings. Confocal 
images of biofilms treated with switchable NZ1 exhibited bright fluorescence, with only localized 
fluorescence observed with NZ2, and little or no fluorescence beyond auto fluorescence observed 




pH responsive zwitterionic nanozyme NZ1 can be used to target the biofilms for imaging 
applications. 
 
Figure 4.3. a) Confocal microscopy images of DS Red exp E. coli and activated Rhodamine 110 
fluorophore in the presence of NZ1. Composite images show homogeneous colocalization of 
biofilm and activated fluorophores. The panels are projections at 0, 45, and 90° angle turning along 
the Y-axis. The scale bars are 20 μm b) Integrated intensity of Rhodamine 110 and DS Red biofilm 
after 1 h incubation with NZ1. The x-axis is the depth of penetration of biofilms, where 0 μm 
represents the top layer and ∼5.6 μm the bottom layer. The y-axis, normalized fluorescence, is 
normalized intensity of red and green channels at the top layer to compare their localization c) Cell 
viability of 3T3 fibroblast cells after 24 h incubation with NZ1−3 (0.1−2 μM). The data are average 
of triplicates, and the error bars indicate standard deviations. 
Z-stack confocal imaging was used to determine the localization of activated fluorophores 
inside DS Red (red fluorescent protein) expressing E. coli biofilms (Figure 4.3a). The penetration 
profile of NZ1 was quantified by using NIS element analysis software.32 The intensity of green and 
red channel represents the intensity of Rhodamine-110 and biofilms respectively. The integrated 
intensities were normalized at the top layer of biofilm to compare their co-localization with varying 
biofilm depth (0-5.6 µm). As shown in Figure 4.3b, the activated fluorophore (Rhodamine 110) 
was distributed throughout the biofilm. Biofilms incubated without NZ1 were used as negative 
control. The ability of switchable NZ1 to image bacterial biofilms was further validated against 
three bacterial strains of clinical isolates - Enterobacter cloacae (CD-1412), methicillin-resistant 
Staphylococcus aureus (CD-489) and Escherichia coli (CD-2), demonstrating effective imaging of 
biofilms formed by both Gram positive (S. aureus) and Gram negative (E. coli, P. aeruginosa, E. 




Fibroblast-cells that maintain high cell viability at 2 µM NZ incubation (Figure 4.3c). These studies 
indicate the biocompatibility of our zwitterionic nanozymes with mammalian cells. 
 
Figure 4.4. Confocal images of a fibroblast-DS Red E. coli biofilm coculture model incubated with 
switchable nanozyme NZ1 (400 nM) and alloc-rhodamine (nonfluorescent, 100 μM) for 1 h. a) DS 
Red, b) Rhodamine 110, and c) merged channels. d) Quantitative analysis of fluorescence intensity 
observed in the images of noninfected cells (cells only) and cells infected with biofilm (coculture). 
Scale bar is 20 μm. 
Imaging of biofilms on biomedical surfaces such as medical implants and indwelling 
devices is a critical capability. However, tracking biofilm-associated infections on human tissues 
and organs is even more challenging and relevant for medical applications. In most cases of 
bacterial infections, microbes are embedded in human tissues inside resilient biofilms comprised 
of EPS.33 Having established that pH responsive NZ1 exhibits the highest selectivity towards 
biofilms and are non-toxic to fibroblast cells, we next investigated their ability to track biofilms, 
using fibroblast-biofilm co-culture as a model. We chose DS Red (red fluorescent protein) 
expressing E. coli as representative strain to generate co-culture model using previously established 
protocols.34 , 35 , 36  Co-cultures were then incubated with NZ1 for 1 hour, followed by multiple 
washings to remove non-adhering NZs. Subsequently, substrate alloc-Rho was added in fresh 
media for 1 hour, followed by multiple washing to remove excess substrate. The co-culture models 
were examined using confocal microscopy, exhibiting strong co-localization of Rhodamine and DS 
Red (from biofilm) and minimal fluorescence around mammalian cells (Figure 4.4, procedure to 
analyze image intensity is described in section 4.5, Figure 4.S7). The co-cultures incubated with 




demonstrates the potential of switchable NZs to image bacterial biofilms in physiologically relevant 
conditions. Their ability to selectively target the biofilms can be attributed to the overall change in 
their surface charge (from neutral to cationic) at acidic conditions. The positively charged NZ1 
shows high accumulation inside the biofilm, whereas the neutral charged NZ1 exhibits minimal 
uptake in fibroblast cells. Hence, the pro-fluorophore gets selectively activated in the biofilm, 
already inhabited by the charge switchable nanozyme.   
4.3 Conclusions 
In conclusion, we have developed a strategy for rapid and effective imaging of biofilms 
that was effective in a complex co-culture model.  The pH-responsive NPs penetrate and 
accumulate inside the acidic microenvironment of biofilms, with bioorthogonal catalysis providing 
a sensitive readout mechanism. This bioorthogonal activation of imaging agents is a promising 
approach to detect biofilm-associated infections, and to locate infected sites during critical 
debridement surgeries. These pH responsive nanozymes offer a broad-spectrum strategy for 
imaging biofilms arising from different and/or mixed bacteria species, circumventing the need for 
designing microbe-specific probes. Considering their enhanced ability to penetrate the biofilm 
matrix, nanozymes hold a strong advantage against currently used imaging probes. In a broader 
context, this study demonstrates the utility of bioorthogonal catalysis for bioimaging. 
4.4 Experimental methods 
4.4.1 Synthesis of Gold Nanoparticles. Ligands were synthesized using previously 
reported procedure.25, 37  AuNPs was prepared through place-exchange reaction of 1-
pentanethiolprotected 2 nm gold nanoparticle (Au-C5) according to previously reported 
procedure.38 Briefly, to the solution of Au-C5 (10 mg) in CH2Cl2 (1 mL) was added the solution of 
ligand 1 (30 mg) in CH2Cl2: MeOH (4:1, 3 mL). After being stirred at rt for 24 h, the solvent was 




nanoparticle was immediately dissolved in MilliQ water and the aqueous solution of the 
nanoparticle was purified by dialysis with distilled water using SnakeSkinTM Dialysis Tubing 
(Thermo Scientific, 10,000 MWCO). 
4.4.2 Catalyst encapsulation in AuNP monolayer. The catalyst, [Cp*Ru(cod)Cl]  (3.0 
mg) was dissolved in 1 ml acetone and the AuNP (20 µM, 0.5 mL) were diluted to a final 
concentration of 5 µM with DI water (1 ml). Then, the catalyst and the AuNP solutions were mixed 
together and acetone was slowly removed by evaporation. During the evaporation, hydrophobic 
catalyst was encapsulated in the particle monolayer to yield to NP_Ru. Excess catalysts which 
precipitated in water were removed by filtration (Millex-GP filter; 25 mm PES, pore Size: 0.22 µm) 
and dialysis (Snake Skin® dialysis tubing, 10K) against water (5 L) for 24 h. Further purifications 
were followed by multiple filtrations (five times, Amicon® ultra 4, 10K) to remove free catalysts. 
The amount of encapsulated catalysts was measured by ICP-MS by tracking 101Ru relative to 197Au 
for NP_Ru. 
4.4.3 Nanozyme kinetics in solution. Allylcarbamate protected Rhodamine 110 (alloc-
Rho) was used as a substrate to test the catalytic activity of the nanozymes. A solution containing 
100 nM nanozyme and 1 µM substrate was prepared in a 96-well plate. 400 nM nanozyme solution 
and 100 nM substrate solutions alone were used as negative controls. The kinetic study was done 
by tracking the fluorescence intensity (Ex: 488 nm, Em: 521 nm, Cutoff: 515 nm) using a Molecular 
Devices SpectraMax M2 microplate reader. 
4.4.4 Biofilm culture. Bacteria were inoculated in LB broth at 37°C until stationary phase. 
The cultures were then harvested by centrifugation and washed with 0.85% sodium chloride 
solution three times. Concentrations of resuspended bacterial solution were determined by optical 
density measured at 600 nm. Seeding solutions were then made in minimal media, M9 broth to 
reach OD600 of 0.1. 500 µL of the seeding solutions were added to each well of the 24-well 




and incubated at room temperature under static conditions for a desired period of 24 hours. 
Planktonic bacteria were removed by washing with PB saline three times.  
4.4.5 Diffusion of nanozymes inside biofilms. After plating bacterial cells in a 24-well 
plate. On the following day, planktonic bacteria were removed by washing with PBS three times. 
and incubated with NZ 1, NZ 2 and NZ 3 (400 nM each) in minimal M-9 media (pH 7.4) for 3 h at 
37 °C. After incubation, biofilms were washed three times with PBS and lysis buffer was added to 
each well. All lysed samples were then further processed for ICP-MS analysis (vide infra) to 
determine the intracellular amount of gold and ruthenium. Diffusion experiments were performed 
independently at least two times and each experiment was comprised of three replicates.  
4.4.6 Confocal imaging of biofilms. 108 bacterial cells/ml were seeded (2 ml in M9 media) 
in a confocal dish and were allowed to grow, old media was replaced every 24 hours. After 3 days 
media was replaced by 400 nM of the NZ 1, NZ 2 and NZ 3 and biofilms were incubated for 1 h, 
biofilm samples incubated with only M9 media were used as control. After 1 h, biofilms were 
washed with PBS three times and were incubated with 100 µM of the substrates for 1 h. The cells 
were then washed with PBS three times. Confocal microscopy images were obtained on a Zeiss 
LSM 510 Meta microscope by using a 60× objective. The settings of the confocal microscope were 
as follows: green channel: λex=488 nm and λem=BP 505-530 nm; red channel: λex=543 nm and 
λem=LP 650 nm. Emission filters: BP=band pass, LP=high pass. 
4.4.7 Mammalian cell viability studies. These experiments were done using previously 
reported protocol.39 Briefly, 20,000 NIH 3T3 fibroblast cells (ATCC CRL-1658) were cultured in 
DMEM medium in presence of 10% bovine calf serum and 1% antibiotic solution. The cells were 
cultured at 37 °C in a humidified atmosphere of 5% CO2 for 48 h. Next, the cells were washed with 
phosphate-buffered saline (PBS) and different concentration of NZs (1-3) in 10% serum containing 
media were incubated with the cells for 3 h at 37 °C. After the incubation period, cells were washed 
with PBS (3 times) and cell viability was then determined using Alamar blue assays according to 




Alamar Blue solution in 10% serum containing media. The solution was incubated at 37 °C under 
a humidified atmosphere of 5% CO2 for 3 h. Subsequently, 200 μl solution from the wells was 
transferred in a 96-well black-microplate. The fluorescence reading was measured using a UV/vis 
spectrophotometer with excitation and emission at 560 and 590 nm respectively. Cell incubated 
without NPs were treated as 100% viable cells and the cell viability was calculated accordingly. 
These experiments were performed in triplicates. 
4.4.8 Imaging of Co-culture models. Fibroblast-3T3 co-culture was performed using a 
previously reported protocol.36 A total of 20,000 NIH 3T3 (ATCC CRL-1658) cells were cultured 
in Dulbecco's modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 
1% antibiotics at 37°C in a humidified atmosphere of 5% CO2. Cells were kept for 24 hours to 
reach a confluent monolayer in a confocal dish. Bacteria (P. aeruginosa) were inoculated and 
harvested as mentioned above. Afterwards, seeding solutions 108 cells/ml were inoculated in 
buffered DMEM supplemented with glucose. Old media was removed from 3T3 cells followed by 
addition of 2 mL of seeding solution. The co-cultures were then stored in a box humidified with 
damp paper towels at 37°C overnight without shaking. The co-cultures were treated with NZs and 
substrates using similar procedure used for biofilm models. 
4.5 Supplementary information 
4.5.1 Stability of NZs at different pH values. Hydrodynamic diameter of the NZs at 
different pH were measured by dynamic light scattering (DLS) in 5mM Phosphate buffer (pH 5.5-
7.4) and 5mM Citrate buffer (pH 3.5-4.5) using a Malvern Zetasizer Nano ZS instrument. The NZs 
(1 µM) were incubated in the respective buffers for 3 hours before each measurement. No 
significant changes in the NZ size were observed. The size distribution by number are presented in 





Figure 4.5. DLS measurements of NZs after 3-hour incubation in buffers with varying pH (3.5-
7.4) indicate that NZ size remains same even at acidic conditions. 
4.5.2 Zeta potential of NZs at different pH values. Zeta potential of the NZs at different 
pH were measured by dynamic light scattering (DLS) in 5mM Phosphate buffer (pH 5.5-7.4) and 
5mM Citrate buffer (pH 3.5-4.5) using a Malvern Zetasizer Nano ZS instrument. The NZs (1 µM) 
were incubated in the respective buffers for 3 hours before each measurement. The zeta potential 





Figure 4.6. Zeta potential of NZs at different pH values, indicating overall change in surface charge 
of NZ1 and NZ2 at pH 6.5 and 4.5 respectively. NZ3 remains neutral in charge throughout the pH 
range. 
4.5.3 Quantification of Au and Ru using ICP-MS characterization. ICP-MS analyses 
were performed on a Perkin-Elmer NexION 300X ICP mass spectrometer to quanify 197Au and 
101Ru. Operating conditions are listed as below: nebulizer flow rate: 0.95 L/min; rf power: 1600 W; 




(concentration: 0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) were prepared for calibration. Nanozyme 
solutions were diluted in water to 200 nM. 10 μL sample solution was transferred to 15 mL 
centrifuge tubes. 0.5 mL of fresh aqua regia was added to each sample including the standard 
samples and was diluted to 10 mL with de-ionized water.  
Sample Preparation: was added to the 10 μL sample solution and then the sample was 
diluted to 10 mL with de-ionized water. 
 
Figure 4.7. Ruthenium amount in the nanozymes using ICP-MS measurement. The Catalyst/NP 
represents number of Ruthenium catalysts encapsulated per gold nanoparticle. 
4.5.4 Nanozyme catalysis in solution at different pH. Allylcarbamate protected 
Rhodamine 110 (alloc-Rho) was used as a substrate to test the catalytic activity of the nanozymes. 
A solution containing 400 nM nanozyme and 100 µM substrate was prepared in a 96-well plate 
using buffers with varying pH (3.5-7.4). 400 nM nanozyme solution and 100 µM substrate solutions 
alone were used as negative controls. The kinetic study was done by tracking the fluorescence 
intensity (Ex: 488 nm, Em: 521 nm, Cutoff: 515 nm) using a Molecular Devices SpectraMax M2 
microplate reader as shown in Figure 4.S4. 5 mM Phosphate buffer were used for pH range (5.5-





Figure 4.8. Catalysis of NZ1 at different pH for 2 hours at 37 ºC. 
  4.5.5 Cellular uptake of NZs in 3T3 Fibroblast cells: The cellular uptake experiments 
were done using previously approved protocols. 30K Fibrobast cell/well were plated in a 24-well 
plate prior to the experiment. Next day, the cells were washed with PBS and incubated with NZ1 
(1 μM) in 10% serum-containing media for 3h at 37 °C. Subsequently, the cells were washed with 
PBS (3 times) and then subjected to lysis buffer. The lysed cells were then further processed for 
ICP-MS analysis as shown in Figure 4.S5. These experiments were performed independently two 
times and each experiment was comprised of 3 replicates.  
4.5.6 Sample preparation for ICP-MS and ICP-MS instrumentation: Samples were 
prepared using previously reported protocols. The cells were lysed by a lysis buffer and were 
transferred to 15 mL centrifuge tubes. A series of standard solutions of gold and ruthenium (0, 0.2, 
0.5, 1, 2, 5, 10, and 20 ppb) were prepared for calibration. 0.5 mL of fresh aqua regia were added 
to each sample including the standard samples and were diluted to 10 mL with de-ionized water. 
197Au and 101Ru quantification were done on a Perkin-Elmer NexION 300X ICP mass spectrometer 
under standard mode. Operating conditions are listed as below: nebulizer flow rate: 0.95-1 L/min; 






Figure 4.9. Nanoparticle and catalyst uptake in P. aeruginosa (CD-1006) biofilms and NIH-3T3 
Fibroblast cells after incubation for 1 hour in pH 7.4 (cell culture media with 10% serum) with NZ1 
(400 nM), as measured by ICP-MS. 
4.5.7 Confocal imaging of 4 different strains: We used the same procedure for imaging 
biofilms as described in the materials and methods section of the manuscript in Figure 4.S6.  
 
Figure 4.10. Confocal microscopy images of a. CD-489 (S. aureus, a methicillin resistant strain), 
b. CD-1006 (P. aeruginosa), c. CD-2 (E. coli) and d. CD-1412 (En. cloacae) treated with 
nanozymes (NZ1) and pro-rhodamine. The panels are projections at 0º and 90º angle turning along 
Y-axis. The scale bars are 20 µm. e) Integrated intensity of Rhodamine 110 after 1-hour incubation 
with NZ1. The x-axis is the depth of penetration of biofilms, where 0 µm represents the top layer. 





4.5.8 Data analysis of confocal images. The data analysis of the confocal images was 
done using the previously reported procedure.40,41 Briefly, confocal images obtained were analyzed 
using ImageJ software. After opening the file in ImageJ, the site of interest was selected using 
drawing selection tool (rectangle). Next, from the analyze menu, “set measurements” was selected 
for determining Area, Integrated density and mean grey value. To obtain final cell/biofilm 
fluorescence, the following formula was used -:  
CTCF = Integrated Density – (Area of selected location × Mean fluorescence of 
background readings)  
An example for the data points obtained for image analysis can be explained using Figure 
S7. Box 1 represents the background, box 2 represents the site for cells only and box 3 represents 
biofilm-mammalian cell coculture in Figure 4.S7. The fluorescence calculated for cells only and 
biofilms was done by selecting 50 similar data points and averaging the results obtained for all 
them.  
 
Figure 4.11. Image showing an example of sites used for image analysis of biofilm-mammalian 
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RBC-MEDIATED DELIVERY OF BIOORTHOGONAL NANOZYMES FOR 
SELECTIVE TARGETING OF BACTERIAL INFECTIONS 
5.1 Introduction 
Bioorthogonal catalysis offers a strategy for chemical transformations complementary to 
bioprocesses and has proven to be a powerful tool in biochemistry and medical sciences.1 - 3 
Nanoparticles embedded with transition metal catalysts (nanozymes) have demonstrated excellent 
ability to catalyze reactions beyond the capabilities of biological systems. 4 , 5  Nanozymes can 
implement bioorthogonal approach to chemically transform a biologically inert substrate to its 
active form at the site of interest.6,7 Localization of bio-orthogonal nanozymes at targeted biological 
site is central in maximizing the efficacy of the strategy.8,9 One approach to control spatiotemporal 
localization of biorthogonal catalysts utilizes tuning the size of carrier. 10 , 11  Alternatively, 
biorthogonal catalysts can be functionalized with different ligands, peptides or biomolecules to 
target the diseased physiological site.7,8 However, these synthetic carrier-based approaches are 
susceptible to non-specific uptake and potential degradation of vehicles in macrophages, 
compromising the efficacy of therapy.12,13 
Red blood cells (RBCs) have been used as cell-based drug delivery systems owing to their 
biocompatibility, long circulation time and low immunogenicity. 14 - 16  RBCs are significantly 
hemolyzed by bacterial toxins, providing these RBC carriers with intrinsic targeting ability towards 
pathogenic bacteria. 17-19 Moreover, high surface to volume ratio of RBCs provides an ideal surface 
for hitchhiking of nanoparticles through supramolecular interactions with RBC cell surface. Recent 
studies have demonstrated that RBC-hitchhiking of NPs enhanced the delivery efficacy to the target 
organs with minimal non-specific uptake by the reticuloendothelial system.20,21  
Notably, maintaining the stability of RBC membranes is critical in retaining the 




dictates their interaction with RBCs and is key to generate RBC “super-carriers” as effective drug 
delivery systems.22  For example, cationic NPs can bind to the anionic glycocalyx on RBC cell 
surface. 23  Similarly, NPs can also bind to hydrophobic domains present on RBC’s plasma 
membranes irrespective of NP surface charge.24 Moreover, tuning hydrophilic and hydrophobic 
moieties on NP-surface can significantly impact the hemolysis caused by NPs.25   
We hypothesized that integration of “super-carrier” RBCs with bioorthogonal nanozymes 
would offer a novel route to combat bacterial infections while minimizing the possible off-target 
effects. Here, we have designed a series of nanozymes that feature diverse functional groups with 
different binding ability to RBCs. The structure-activity studies revealed that hydrophilic cationic 
NZs can stably attach onto RBC surface, resulting in formation of RBC-hitchhiked nanozymes 
(RBC-NZs). Subsequently, these RBCs were hemolyzed by bacterial toxins, resulting in 
accumulation of nanozymes at the site of bacterial infection. These NZs activated protected-
antibiotic molecules and effectively eradicate biofilms formed by uropathogenic bacteria, whereas 
minimal toxicity was observed against non-virulent bacterial strains. Moreover, RBC-NZs showed 
minimal uptake in macrophage cells as opposed to free nanozymes, suggesting that nanozyme 
hitchhiking does not compromise the immune-evading ability of RBCs. Overall, we have generated 
RBC-hitchhiked nanozymes illustrating the ability of passively targeting bacterial infections 




5.2 Results and discussion 
 
Figure 5.1. a) Molecular structures of the ligand structures used on nanozymes used in the RBC-
adsorption study. b)  Structures of the substrates Resorufin and moxicillin derivative (Pro-Res, Pro-
Mox) and products (Resorufin, Moxifloxacin) after cleavage by TMC c) Schematic representation 
showing hitchhiking of NZs on Red Blood Cells, selective targeting of biofilms infections due to 
lysis of RBCs in presence of bacterial toxins and intrabiofilm generation of antibiotics by transition 
metal catalysts (TMCs) embedded in the nanoparticle monolayers.   
Nanozymes were fabricated using AuNPs with ~ 2 nm core diameter as scaffolds. AuNPs 
were functionalized with ligands featuring three main components: (1) a hydrophobic alkyl chain 
interior enabling encapsulation of hydrophobic catalysts, (2) tetra ethylene glycol spacer providing 
biocompatibility and (3) terminal groups dictating NP-binding with Red Blood Cells.26 Aqueous 
solution of AuNPs was mixed with catalysts (iron (III) tetraphenyl porphyrin (FeTPP)) dissolved 
in organic solvents in 1:1 ratio (% v/v). The mixture was slowly evaporated to remove organic 
solvents, resulting in encapsulation catalysts in the surface monolayer of AuNPs to form 




centrifugal filter and dialysis (experimental details are provided in methods section).27The chemical 
functionality of NZ-surface ligands plays a critical role in determining their compatibility with 
RBCs, in-turn dictating ability of NZs to hitchhike on RBC surface.20,23 We synthesized a family 
of NPs (1-9) with varying surface charge, hydrophobicity and aromatic properties using ligand 
place exchange reactions with pentanethiol-capped 2 nm Au core (detailed description for synthesis 
of NPs is described in Supporting Information). NPs (1-9) were used to fabricate NZs (1-9) and 
characterized using dynamic light scattering (DLS) (Figure 5.S1, Table 5.S1) and transmission 
electron microscopy (TEM, Figure 5.S2). TEM and DLS results showed no signs of aggregation of 
NZs upon catalyst encapsulation. The number of catalysts encapsulated were quantified using 
inductively coupled mass spectrometry (ICP-MS, Table 5.S2), indicating that 30±6 catalyst 
molecules were encapsulated per AuNP for NZ 1-9.          
Our initial focus was to adsorb NZs on RBCs without compromising the stability of cell 
membrane, hence we screened the library of NZs for hemolytic activity against RBCs both in PBS 
and serum-containing media. NZs (1-9) were incubated with RBCs for 30 minutes and the 
absorbance of released hemoglobin was measured at 570 nm. 28  We observed that cationic 
hydrophilic NZs (NZ 1-2) showed minimal hemolysis as compared to their hydrophobic 
counterparts. Similarly, anionic and zwitterionic NZs (NZ 7-9) showed minimal hemolysis of 
RBCs (Figure 5.2a, 5.S3), consistent with previously reported studies.25 Next, we studied the 
adsorption of non-hemolytic NZs (NZ1-2, NZ7-9) on RBCs to determine their suitability for RBC 
hitchhiking. NZs were incubated with RBCs for 30 minutes and washed to remove excess NZs. 
The harvested RBCs were then analyzed using ICP-MS to quantify gold content on the cells. 
Cationic NZs showed significant adsorption on RBCs as compared to the anionic and zwitterionic 
NZs (Figure 5.2b), attributed to electrostatic interactions between NZs and RBCs. 
Nanoparticles can frequently detach from RBCs due to shear force and lose their targeting 
ability.24 Hence, we further investigated the stability of NZs hitchhiked on RBCs by subjecting 




content was observed even after 5 centrifuging cycles, indicating that NZs remain attached to RBCs 
(Figure 5.2c). Adsorption of NZ 1 on RBCs was further investigated at a reduced incubation time 
of 30 minutes (Figure 5.2d). The catalytic activity of RBC-NZs was assessed by fluorometric 
measurement of resorufin molecule fragmented from the non-fluorescent pro-Res (Figure 5.1b) due 
to azide reduction by FeTTP catalyst in presence of glutathione (1 mM).29 Linear increase in the 
fluorescence indicate that NZs retain their catalytic activity even after adsorption on RBCs. The 
rate of fluorescence increase was similar for free NZs as compared to RBC-NZs (500 nM). 
Moreover, catalytic rate of RBC-NZs increased linearly with increasing concentration of RBC-NZs 
(50-100 nM) as seen in Figure 5.2e. RBC-NZs incubated with pro-Res and glutathione were 
visualized under confocal microscope, further indicating that RBC-NZs retain their catalytic 
activity.   
Figure 5.2. a) Dose-dependent hemolytic activity of NZ 1–NZ 9 in the absence of plasma proteins. % 
hemolysis was calculated using water as the positive control. Error bars represent standard 
deviations (n = 3). Amount of NZ adsorption on Red Blood Cells after b) incubation for 30 minutes 
c) after multiple cycles of centrifugation, at a concentration of 500 nM, as measured using ICP-MS. 
Dose dependent d) hemolytic activity of NZ 1 for 107 Red Blood Cell/mL, e) NZ adsorption for 





RBCs lose their prolonged circulation upon damage to RBC plasma membrane such as 
those caused by pore-forming toxins (PFTs).16,19 Infections caused by bacteria often involve 
secretion of pore-PFTs as a virulence mechanism.30,31 These toxins disrupt the host-cell membrane 
for pathogenesis, in particular causing high hemolysis of RBCs. For example, α-hemolysin toxin 
released by S. aureus and E. coli is one of the key virulence factors of the invading strains.17,32,33 
Next, we investigated the hemolysis of RBCs caused by uropathogenic clinical isolates (E. coli, 
methicillin-resistant S. aureus (MRSA)) and non-pathogenic laboratory strains (P. aeruginosa, B. 
sub). We observed that uropathogenic strains caused complete hemolysis of the RBCs within 30 
minutes of incubation with RBCs, whereas the non-pathogenic strains caused minimal hemolysis 
of RBCs (Figure 5.3a). Having established that cationic hydrophilic NZs can hitchhike onto RBCs 
and these RBCs were hemolyzed in presence of bacterial infections. We set out to determine 
whether hemolysis of RBCs could result in selective catalytic activity of RBC-NZs against 
pathogenic bacterial infections. 
Conventional antibiotic-based strategies to combat bacterial infections often disrupt the 
ecology of human microbiome by killing helpful bacteria species inhabiting the host.34,35 Hence, it 
is critical to develop strategies with increased efficacy to target pathogenic infections.36,37 We 
investigated the selectivity of RBC-NZs towards virulent biofilms through imaging studies using 
confocal microscopy. Studies for imaging biofilms were based on generation of fluorophore 
(Resorufin) through aryl-reduction of non-fluorescent precursor (Pro-Res) as shown in Figure 
1b.26,29 RBC-NZs were incubated with toxin-secreting (Green Fluorescent Protein (GFP) 
expressing methicillin-resistant Staphylococcus aureus, MRSA) and non-virulent (GFP expressing 
E. coli) bacterial biofilms for 24 hours. Biofilms were then washed multiple times, followed by 1-
hour incubation with substrate and subsequent washings. Uropathogenic biofilms showed bright 
red fluorescence when observed under confocal, with minimal fluorescence observed in non-




can completely penetrate the EPS matrix of biofilm, indicating their potential as an effective 
therapeutic strategy.38  
After establishing selective catalytic activity of RBC-NZs in pathogenic biofilms, we tested 
the accumulation of RBC-NZs using ICP-MS in pathogenic and non-pathogenic biofilms. We 
observed that RBC-NZs showed high accumulation in toxin-secreting uropathogenic bacterial 
biofilms based on Au, whereas minimal amount of Au was observed in non-hemolytic bacterial 
biofilms (Figure 5.3c), whereas free NZ 1 showed similar accumulation in pathogenic and non-
pathogenic biofilms (Figure 5.S4). These results are consistent with our observations indicating 
pathogenic bacteria cause higher hemolysis of biofilms as compared to their non-pathogenic 
counterparts. In another experiment, we determined the amount of Au attached to the cell debris 
upon hemolysis of RBCs to understand the association of NZs with the carrier cells. It was 
determined that significant number of NZs were released into the solution upon hemolysis of RBCs, 
whereas NZs remained attached to cell-surface in case of non-hemolyzed RBCs (Figure 5.3d). This 
phenomenon could be attributed to compromised electrostatic interaction between NZs and RBCs 
upon lysis of the erythrocyte cells.39   
After establishing the ability of RBC-NZs to selectively target pathogenic bacterial 
biofilms, we probed the immunocompatibility of RBC-NZs. RAW 264.7 macrophage cells were 
incubated with RBC-NZs for 24 hours, followed by washing and addition of pro-Res for 24 hours. 
It was observed that macrophages incubated with RBC-NZs exhibited minimal fluorescence, 
whereas macrophages incubated with free NZ 1 (Bare-NZ) showed strong punctate fluorescence 
due to activation of pro-fluorophore by macrophage uptaken nanozymes (Figure 5.5). Additionally, 
free NZ 1 (bare-NZ) showed high uptake in macrophages whereas RBC-NZs showed minimal 
uptake as quantified by ICP-MS (Figure 5.3c, 5.6). These results further suggest that RBC 
hitchhiking can be used to selectively target pathogenic biofilms while avoiding non-specific 





Figure 5.3. a) Hemolysis of Red Blood Cells by bacterial biofilms b) Quantification of Au (ng/well) 
on RBCs-nanozymes incubated in PBS and Triton-X c) Nanozyme diffusion of Au (ng/well) in 
different bacterial biofilms including pathogenic (methicillin-resistant S. aureus, MRSA and E. 
coli) and non-virulent (P. aeruginosa ATCC 17660, B. Sub FD6b) biofilms after incubation for 1 
day with RBC-NZ (107 cell/mL, 100 nM NZ), as measured by ICP-MS. Cellular uptake of Au 
(ng/well) in macrophage (RAW 264.7) (20,000 cells/well) after incubation for 1 day with RBC-NZ 
(107 cell/mL, 100 nM NZ), as measured by ICP-MS d) Confocal images of biofilms incubated with 
RBC-NZs (1 h) followed by incubation with Pro-Res (1 h, 10 μM). 
After establishing the localization of NZs at the site of pathogenic bacteria, we investigated 
the ability of RBC-NZs to selectively activate antibiotic-precursor and eradicate pathogenic 
bacterial biofilms. For this study, aryl azide protected moxifloxacin (pro-Mox) was chosen as a 
model pro-antibiotic due to the high clinical relevance of moxifloxacin in the treatment of MDR 
infections.40 The synthetic protection of secondary amine group on moxifloxacin inhibits them to 
bind with target bacterial enzymes, inhibiting their antimicrobial activity prior to activation.41 
Alamar Blue assays were performed on biofilms treated with RBC-NZs and pro-Mox to determine 





Figure 5.4. Deprotection of antimicrobials in biofilms using RBC-hitchhiked nanozymes. RBC-
NZ was used for selective activation of antibiotic prodrugs that decrease biofilms viability. a) E. 
coli (toxin producing) biofilms and b) B. sub (non-virulent) biofilms treated with pro-Mox and 
RBC-NZ (red bars) at 37 oC. Biofilms treated only with pro-Mox (blue bars) or with Mox (grey 
bars) were used in all experiments as negative and positive controls, respectively. Biofilm viability 
of c) hemolytic (pathogenic) and d) non-pathogenic bacterial strains after treatment with RBC-NZ 
and pro-Mox and moxifloxacin antibiotic alone. Each experiment was replicated five times. Error 
bars represent standard deviations of these measurements. *p < 0.05, ***p < 0.001 
We chose methicillin-resistant S. aureus (MRSA) and E. coli for biofilm viability 
studies due to their high clinical relevance and pathogenicity caused by α-hemolysin toxin 
secreted by these species.17,18,36 Non-pathogenic bacterial strains of P. aeruginosa, B. sub 
were used as models strains to study the effect of RBC-NZs on non-hemolytic strains. 
Biofilms were incubated with RBC-NZs (500 nM) for 24 hours, washed and subsequently 




in methods section). Cells incubated with only pro-Mox and moxifloxacin antibiotics were 
used as negative and positive controls respectively (Figures 5.4, 5.S7, 5.S8). It was 
observed that pro-Mox did not reduce biofilm viability against both pathogenic and non-
pathogenic biofilms. However, pro-Mox incubated with RBC-NZs showed reduced 
biofilm viability of pathogenic biofilms while no significant antimicrobial activity was 
observed against non-pathogenic biofilms. These results indicate that selective 
accumulation of NZs in pathogenic biofilms enabled catalytic activation of pro-antibiotics 
thereby increasing the specificity of the therapy. Moreover, moxifloxacin reduced bacterial 
viability of both pathogenic and non-pathogenic species, indicating the non-selective 
bacteria killing caused by antibiotic treatment.  
5.3 Conclusions 
Taken together, we have developed a strategy that integrates natural carrier RBCs with 
biomimetic nanozymes, providing a platform to perform abiotic chemical reactions with targeting 
ability in physiological conditions. In this study, we have utilized RBC-hitchhiked nanozymes to 
selectively eradicate pathogenic bacterial infections. RBCs are hemolyzed in presence of toxins 
secreted by pathogenic bacteria resulting in selective accumulation of nanozymes at the site of 
infection. These accumulated nanozymes can subsequently activate antibiotics at the diseased site 
and eradicate pre-formed biofilms, without harming non-virulent bacterial species. Moreover, 
RBC-hitchhiked nanozymes show minimal immune response strengthening their claim as a potent 
in vivo therapeutic. With the ability to act as inactive reservoirs this strategy can be particularly 
useful in treating recurring bacterial infections including chronic wounds and medical device 
associated infections. This strategy can be further explored to activate multiple therapeutic 
molecules at the targeted site to combat complex infections and promote healing of the surrounding 




controlled and potentially “incessant” therapeutic loading while circumventing the limitations 
associated with delivery of nanovehicles. Modular nature of this approach makes it suitable for 
numerous imaging and therapeutic applications for diverse range of diseases.  
5.4 Experimental methods 
5.4.1 NP synthesis. 2nm diameter gold nanoparticles were synthetized by the Brust-
Schiffrin two-phase methodology using pentanethiol as the stabilizer; these clusters were purified 
with successive extractions with ethanol and acetone. A Murray place exchange reaction was 
carried out in dry DCM to functionalize the nanoparticles with each ligand.42,43 The monolayer-
protected nanoparticles were redispersed in water and the excesses of ligand/pentanethiol were 
removed by dialysis using a 10,000 MWCO snake-skin membrane. The final concentration was 
measured by UV spectroscopy on a Molecular Devices SpectraMax M2 at 506 nm according to the 
reported methodology.44 
5.4.2 Hemolysis assay. Hemolysis assay was performed on human red blood cells as we 
described in previous study.45 Briefly, citrate-stabilized human whole blood (pooled, mixed gender) 
was purchased from Bioreclamation LLC, NY. The red blood cells were purified and re-suspended 
in 10 mL phosphate buffered saline as soon as received. 0.1 mL of RBC solution was added to 0.4 
mL of NP solution in PBS in 1.5 mL centrifuge tube.  
The mixture was incubated at 37 ˚C, 150 rpm for 30 minutes followed by centrifugation at 
4000 rpm for 5 minutes. The absorbance value of the supernatant was measured at 570 nm with 
absorbance at 655 nm as a reference. RBCs incubated with PBS as well as water were used as 
negative and positive control, respectively. All samples were prepared in triplicate. The percent 
hemolysis was calculated using the following formula:  
% Hemolysis = ((sample absorbance-negative control absorbance)) / ((positive control 




5.4.3 Biofilm culture. Bacteria were inoculated in LB broth at 37 °C until stationary phase. 
The cultures were then harvested by centrifugation and washed with 0.85% sodium chloride 
solution three times. Concentrations of resuspended bacterial solution were determined by optical 
density measured at 600 nm. Seeding solutions were then made in minimal media, M9 broth to 
reach OD600 of 0.1. Then, 500 μL of the seeding solutions was added to each well of the 24-well 
microplate. M9 medium without bacteria was used as a negative control. The plates were covered 
and incubated at room temperature under static conditions for a desired period of 24 h. Planktonic 
bacteria were removed by washing with phosphate-buffered saline (PBS) three times. 
5.4.4 Nanozyme accumulation in biofilms. After plating bacterial cells in a 24-well plate. 
On the following day, planktonic bacteria were removed by washing with PBS three times and 
incubated with RBC-NZ, Bare-NZ (107 RBC/ml, 500 nM respectively) in minimal M-9 media (pH 
7.4) for 1 h at 37 °C. After incubation, biofilms were washed three times with PBS, and lysis buffer 
was added to each well. All lysed samples were then further processed for ICP-MS analysis (vide 
inf ra) to determine the intracellular amount of gold and ruthenium. Diffusion experiments were 
performed independently at least two times, and each experiment comprised three replicates. 
5.4.5 Confocal Imaging of Bacteria. A total of 108 bacterial cells/mL was seeded (2 mL 
in M9 media) in a confocal dish and allowed to grow; old medium was replaced every 24 h. After 
3 days, medium was replaced by RBC-NZ and biofilms were incubated for 1 h; biofilm samples 
incubated with only M9 media were used as the control. After 1 h, biofilms were washed with PBS 
three times and were incubated with 10 μM of the substrates for 1 h. The cells were then washed 
with PBS three times. Confocal microscopy images were obtained on a Zeiss LSM 510 Meta 
microscope by using a 60× objective. The settings of the confocal microscope were as follows: 
green channel, λex = 488 nm and λem = BP 505−530 nm; red channel, λex = 543 nm and λem = 




5.4.6 Prodrug activation: Biofilms were cultured as mentioned in the above section. 
Biofilms were washed off and incubated with RBC-NZ (500 nM) in minimal M9 media. After 24 
h, biofilms were washed with PBS buffer three times and treated with pro-Mox at a concentration 
of 2.5, 5, 10 µM for 24 h. The cells were then completely washed off and 10% alamar blue in 
minimal media was added to each well (220 µl) and incubated further at 37°C for 2 h. Biofilm 
viability was then determined by measuring the fluorescence intensity at 570 nm using a 
SpectraMax M5 microplate spectrophotometer.  
5.5 Supplementary information 
5.5.1 DLS characterization of nanozymes. The hydrodynamic diameter of the 
nanozymes were measured by dynamic light scattering (DLS) in DI water using Malvern Zetasizer 
Nano ZS instrument. The measurement setting were as follows: angle: 173° (backscatter), “multiple 
narrow modes” (high resolution) based on non-negative-least-squares (NNLS).  
 
Figure 5.5. DLS measurements of NZ 1 - NZ 9. 
Table 5.1. The size of nanozymes obtained from DLS. 
Nanozymes Size (d.nm) 
NZ 1 9.1 ± 2.1 
NZ 2 9.8 ± 2.3 
NZ 3 8.7 ± 3.5 




NZ 5 8.1 ± 1.9 
NZ 6 8.1 ± 2.4 
NZ 7 8.1 ± 3.7 
NZ 8 8.4 ± 4.1 
NZ 9 9.4 ± 2.9 
 
5.5.2 TEM characterization of nanozymes. Transmission Electron Microscopy (TEM) 
images of samples were taken using JEOL CX-100 electron microscopy. Samples were prepared 
by placing one drop of the desired solution onto a 300-mesh Cu grid-coated with carbon film. No 
aggregation was observed after catalyst encapsulation.  
 
Figure 5.6. TEM images of nanozymes. Scale bar = 20 nm. 
5.5.3 Quantification of catalyst per AuNP using ICP-MS characterization. The 
catalysts were quantified using previously established protocols. 46  Briefly, the nanoparticle 




replicate. 0.5 mL of aqua regia was added to each replicate and was diluted to 10 mL by adding 
milli-Q water. The amount of encapsulated catalysts was measured by a Perkin-Elmer NexION 
300X ICP mass spectrometer by tracking 56Fe relative to 197Au. For calibration, a series of solutions 
with gold and iron (concentration: 0, 0.2, 0.5,1, 2, 5, 10, and 20 ppb) were prepared. Operating 
conditions were as follows: nebulizer flow rate: 0.95 L/min; rf power: 1600 W; plasma Ar flow 
rate: 18 L/min; dwell time: 50 ms. 
Table 5.2. Gold (Au) and iron (Fe) amount in the nanozymes using ICP-MS measurement. 
The Fe/AuNP represents number of catalysts encapsulated per AuNP. 
Nanozymes  Au(ppb) Fe(ppb) Fe/AuNP 
1 24.6 1.2 35.6 ± 2.1 
2 27.7 1.3 33.2 ± 1.1 
3 27.3 1.1 34.8 ± 5.9 
4 24.6 0.9 34.9 ± 3.6 
5 27.1 1.4 33.1 ± 1.8 
6 25.9 1.1 35.4 ± 7.1 
7 26.6 1.2 30.2 ± 10.3 
8 22.9 1.0 30.7 ± 9.9 
9 28.7 1.2 31.1 ± 8.2 
 
5.5.4 Hemolysis assays with nanozymes. Hemolysis assays on red blood cells were 
performed using previously reported protocols.47  Briefly, human whole blood (pooled, mixed 
gender) was purchased from Bioreclamation LLC, NY and processed as soon as received. 10 ml 
phosphate buffered saline (PBS) was added to the blood and centrifuged for 5 minutes at 5000 
r.p.m. Supernatant was discarded followed by redispersion of RBCs in 10 ml of PBS. This cycle 
was repeated at least 5 times. Finally, RBCs were diluted in 10 ml of PBS and kept on ice during 
sample preparation. 0.4 ml of NZs (different concentrations) were prepared in a 1.5 ml Eppendorf 
tube, followed by addition of 0.1 ml of RBC solution. RBCs incubated with water and PBS were 
used as negative and positive controls respectively and all the samples were prepared in triplicates. 
These mixtures were incubated at 37 °C, 150 r.p.m for 24 hours. The mixtures were then 




The absorbance of supernatant was measured at 570 nm using Molecular Devices SpectraMax M2 
microplate reader with 655 nm as a reference.   
5.5.5 Nanozyme adsorption on RBCs. RBCs were isolated from human whole blood as 
described in the above section. Next, nanozymes (NZ 1-9) with varied concentrations (100 – 1000 
nM) were incubated with RBCs in PBS for 1 hour at 37 °C, 150 r.p.m. The NZ-RBC mixture were 
then washed with PBS five times at 4000 r.p.m for 5 minutes to remove excess NZs in the solution. 
The isolated RBCs were then processed for ICP-MS analysis and quantified for gold content.  
 
 
Figure 5.7. Dose-dependent hemolytic activity of NZ 1–NZ 9 in the presence of plasma 
proteins. % hemolysis was calculated using water as the positive control. Error bars represent 
standard deviations (n = 3). 





Compound 1 was synthesized from the corresponding aminated compound. A solution of 
4-aminobenzyl alcohol (2.15 g, 17.5 mmol) was dissolved in THF (25 mL) and mixed with an 
aqueous solution of H2SO4 (4.8 mL 98%, in 60 mL of water) cooled at 4 oC in a round bottom flask. 
An aqueous solution of NaNO2 (1.45 g, 21 mmol) was added to the solution and was allowed to 
react for 1 h in ice bath. An aqueous solution of NaN3 (1.8 g, 28.9 mmol) was added to the solution. 
The mixture was led to react overnight followed by collecting 4-azidobenzyl alcohol by three 
liquid-liquid extraction processes using dichloromethane (100 mL). Fractions were collected and 
dried over anhydrous Na2SO4, concentrated and purified by flash column chromatography (DCM: 
MetOH 19:1). Yield 84%. 
5.5.7 Nanozyme kinetics in solution. Pro-res (non-fluorescent) was used as a substrate to 
test the catalytic activity of the nanozymes. A solution containing 10 μM substrate and RBC-NZs 
(100 – 1000 nM) was prepared in a 96-well plate. A solution of 500 nM free nanozyme (Bare-NZ) 
with 10 μM substrate was used for comparison. Solutions of RBC-NZs, 10 µM substrate, RBCs 
alone were used as negative controls. The kinetic study was done by tracking the fluorescence 
intensity (ex = 561 nm, em = 590 nm) using a Molecular Devices SpectraMax M2 microplate reader. 
5.5.8 Biofilm Culture. Biofilms were cultured as reported in previously established 
protocols. Briefly, bacteria were grown overnight in LB media at 37 ˚C until to reach stationary 
phase. Bacteria cultures were then centrifuged and washed three times using 0.85% sodium chloride 
solution. Bacteria were resuspended in PBS and their concentrations were determined using optical 
density measurements at 600 nm. Seeding solutions were made in M9 media to reach an OD600 of 
0.1. 500 µL of the seeding solutions were added to each well of the 12-well microplate (100 µl 
seeding soltions were used for 96-well plates). The plates were covered and incubated at room 
temperature for 24 hours in static conditions.  
5.5.9 Hemolytic activity of bacterial strains. Biofilms were cultured in a 12-well plate 




suspended in PBS. 500 µl of RBC solution was added to the 12-well plates containing biofilms and 
incubated at 37 °C, 150 rpm for 30 minutes and 24 hours. RBC solution incubated in PBS and milli-
q water (500 µl) were used positive and negative controls respectively. Solutions from 12-well plate 
were collected in a 1.5 ml eppendorf tubes and centrifuged at 4000 rpm for 5 minutes. The 
supernatant was transferred to a clear 96-well microplate and absorbance was measured at 570 nm 
using Molecular Devices SpectraMax M2 microplate reader with reference at 655 nm.     
5.5.10 Nanozyme accumulation studies in biofilms. 0.1 OD600 bacterial cells were plated 
in a 12-well plate for 24 hours. On the following day, media was replaced with fresh M9 minimal 
media and further incubated for 24 hours. Biofilms were then washed three times with PBS, 
followed by incubation with RBC-NZs (500 nM) in minimal M9 media for 24 hours at 37 °C. 
Biofilms incubated with free NZs (Bare-NZs) and media alone were used as controls. After 
incubation, the biofilms were washed with PBS three times, followed by addition of lysis buffer to 
each well. All lysed samples were then further processed for ICP-MS analysis (vide infra) to 
determine the intrabiofilm amount of gold. Nanozyme accumulation experiments were performed 
at least two times, and each experiment comprised three replicates. 
 
Figure 5.8. Amount of gold (Au) accumulated in biofilms obtained from ICP-MS upon treatment 
with free NZ 1. 
5.5.11 Confocal imaging of biofilms. 108 cfu/ml of GFP expressing methicillin-resistant 
S. aureus supplemented with 1mM of IPTG (isopropyl β-D-1-thiogalactopyranoside) bacteria 
solution (2 ml in M9 media) was seeded in a confocal dish and allowed to grow for 3 days. Old 




biofilms were incubated for 3 hours. Biofilms were then washed with PBS three times to remove 
excess NZs or RBC debris from the solution, followed by addition of 20 µM Pro-Res (substrate) 
for 1 hour. The biofilms were then washed three times with PBS and visualized under a confocal 
microscope. Confocal images were obtained on a Zeiss LSM 519 Meta microscope by using a 63× 
objective. The settings of the confocal microscope were as follows: green channel: λex=488 nm and 
λem=BP 505-530 nm; red channel: λex=543 nm and λem=LP 650 nm. Emission filters: BP=band pass, 
LP=high pass. 
5.5.12 Synthesis of aryl-azide protected moxofloxacin substrate (pro-Mox). 
 
The compound 3 (100 mg, 1 eq) was added to a rounded bottom flask containing a solution of Mox 
(100 mg, 0.75 eq) and 50 mg of solid NaHCO3 (1.2 eq) in anhydrous DMF (5 mL). The mixture 
was left to react overnight. Cold water was added and the product was extracted by washing with 
ethyl acetate. All organic fractions were then collected and dried over anhydrous Na2SO4, 
concentrated and purified by recrystallization in ethyl acetate. Yield 64 %.  
5.5.13 Cellular uptake experiments.  20,000 RAW 264.7 macrophage cell lines 
(purchased from American Type Culture Collection, Manassas, VA) were cultured in Dulbecco's 
modified Eagle medium (DMEM; ATCC 30-2002) in the presence of 10% bovine calf serum and 
1% antibiotic solution at 37 ºC in a humidified atmosphere of 5% CO2 for 48 h. Old medium was 
replaced and washed with PBS. Meanwhile, RBC-NZs (100, 250 and 500 nM) solutions were 
prepared in prewarmed 10% serum containing media. Next, the cells were incubated with RBC-
NZs (100, 250 and 500 nM) in 10% serum-containing media for 24 h at 37 °C. Free nanozymes 




treated with lysis buffer. Lysed cells were then processed for ICP-MS analysis. Each experiment 
comprised of 3 replicates.   
5.5.14 Confocal imaging of macrophage cells. Macrophages were seeded in a confocal 
disc at a concentration of 200,000 cells/mL in a 10% serum containing media. After 24 h, the cells 
were treated with RBC-NZ and were stored in incubator for overnight. Next, the cells were washed 
three times with PBS and were incubated with pro-resorufin for 0.5 h. Hoechst 33342 was used as 
a nuclear staining dye. The cells treated with free NZ and proflurophore only were used as positive 
and negative controls respectively.  
 
Figure 5.9. Confocal images of macrophage cells (RAW 264.7) incubated with RBC-NZ and Bare-
NZ in presence of pro-resorufin. No fluorescence was generated by RBC-NZ, indicating that the 
RBC-hichhiked nanozymes were not uptaken by macrophages. Hoechst 33342 was used as a 





Figure 5.10. Nanoparticle uptake by RAW 264.7 macrophage cells biofilms after incubation for 
24 h in pH 7.4 media with Bare-NZ and RBC-NZ (500 nM), as measured by ICP-MS. These results 
indicate that RBC hitchhiking prevents uptake of NZ 1.  
5.5.15 Biofilm treatment using pro-antibiotic activation. 108 cfu/ml of bacteria seeding 
solution was prepared in minimal M9 media. 100 µl of the seeding solution was added to each well 
of the 96-well microplate. The plates were covered and incubated at room temperature for 24 hours 
at static conditions. On the following day, solution of RBC-NZs was prepared in M9 media and 
diluted to desired levels and incubated with biofilms for 24 hours at 37 °C overnight without 
shaking. Biofilms were then washed with PBS to remove unattached NZs or RBC debris, and 
incubated with pro-mox (1-10 µM) diluted in M9 minimal media for 24 hours at 37 °C. The cells 
were then washed three times with PBS and incubated with 10% alamar blue in minimal M9 media 
for 3 hours at 37 °C. Biofilm viability was then determined by measuring fluorescence intensity at 
570 nm using a Molecular Devices SpectraMax M2 microplate reader. Biofilms incubated with 





Figure 5.11. Viability % of biofilm treated with bare-NZ with increasing concentration of pro-Mox. 
 
 
Figure 5.12. Deprotection of antimicrobials in biofilms using RBC-hitchhiked nanozymes: a) E. 
coli (toxin producing) biofilms and b) B. Sub (non-pathogenic) biofilms treated with pro-Mox and 
RBC-NZ (red bars) at 37 °C. Biofilms treated only with pro-Mox (blue bars) or with Mox (grey 
bars) were used in all experiments as negative and positive controls, respectively. Each experiment 
was replicated five times. Error bars represent standard deviations of these measurements. *p < 
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